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Abstract
Fair balance of benefit and risk information in consumer prescription drug advertising
(DTCA) has received much research attention. In this regard, it has been well-documented that
varying levels of risk disclosure prominence have disproportional effects on consumer response
to the DTC ad. However, little research has examined how the prominence effects can be
maximized or minimized depending on consumers’ varying levels of knowledge of the FDA’s
regulatory role for DTCA. In a similar vein, rare research has been conducted to investigate how
such regulatory knowledge directly affects consumers’ risk disclosure coping strategies.
Drawing on consumer information processing perspectives, this research employs an
experimental approach to examine one manipulated categorical variable, one measured
continuous variable, and their interactive effects on consumer response to the ad, while
controlling for potential covariates. Specifically, two levels of risk disclosure prominence are
manipulated (high vs. low) and coded as a dummy variable, and DTCA regulatory knowledge is
measured as a continuous variable. Further, based on the persuasion knowledge model (PKM)
framework, DTCA regulatory knowledge is tested as a moderator of the prominence effects.
Consumer memory such as unaided-recall and aided-recognition of the health risks of the
medicine presented in the ad as well as self-reported perceived attention to risk disclosure are
addressed as criterion variables.
The major findings are summarized as follows: (1) both higher DTCA regulatory
knowledge and higher prominence enhanced perceived attention to risk disclosure; (2) both
higher DTCA regulatory knowledge and higher prominence enhanced consumer recognition of
risk information; (3) DTCA regulatory knowledge moderated the prominence effects on
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perceived attention to risk disclosure; (4) the main DTCA regulatory knowledge effects and the
main prominence effects on consumer recall and recognition were mediated through perceived
attention to risk disclosure; (5) However, the moderated mediation effect analyses revealed that
the effects of prominence on recall and recognition were mediated through perceived attention
among low DTCA regulatory knowledge consumers, whereas the mediating effects were
minimal among high DTCA regulatory knowledge consumers.
The overall findings support the current study’s conceptual framework. The theoretical,
managerial, and consumer education/public health implications of this research are discussed.
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CHAPTER 1: INTRODUCTION
Research Problem
Given that today’s health care patients are increasingly referred to as consumers (Hibbard
& Weeks, 1987; Tomes, 2006), health care consumerism is defined as consumers’ autonomy in
their health care management (Hibbard & Weeks, 1987). In this regard, Almond (2001) suggests
that the terms partnership and participation are regarded as appropriate labels for the consumeroriented contemporary health care context. In order to achieve sound healthcare partnership
participation, consumers must be provided with accurate and comprehensive health information
to make informed health choices, including information about available medical remedies and
their potential health risks. Direct-to-consumer prescription drug advertising (DTCA) represents
one important health information source (Royne & Myers, 2008; Macias, Pashupati, & Lewis,
2007; Macias, Lewis, & Baek, 2010), and therefore it is critical to consider how consumers’
perception regarding health issues are influenced by DTCA health information (Park, Ju, & Kim,
2013; Ju & Park, 2013).
However, despite the presumed importance of DTCA, the literature has found that most
DTC ads tend to present information about the uses and efficacy of the medicine more
prominently than its possible health risks (e.g., Avery, Eisenberg, & Simon, 2012; Davis, Cross,
& Crowley, 2007; Davis & Meader, 2009; Huh & Cude, 2004; Kaphingst, Dejong, Rudd, &
Daltroy, 2004; Macias et al., 2007; Macias et al., 2010; Sheehan, 2007). In line with this finding,
the Federal Food, Drug, and Cosmetic Act (hereinafter, FFD&C Act; 21 U.S.C. 352) requires
pharmaceutical advertisers to present any word, statement, or other information prominently to
be noticed, attended and processed by the ordinary individual under customary conditions of
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purchase and use. Especially, regarding important health risk information in DTC ads,
pharmaceutical advertisers are obligated to prominently provide risk disclosure to be comparable
with benefit and use information in their promotional materials, a policy commonly referred to as
the fair balance requirement (21 Code of Federal Regulation 202.1; hereinafter, 21 CFR 202.1).
The FDA (2009) provides specific guidance to pharmaceutical advertisers regarding how
they must present important health risks of the medicine in DTCA. For instance, risk information
prominence is considered an important aspect, and it could consist of various message execution
factors such as typography, layout, contrast, headlines, paragraphing, white space, and other
techniques used to achieve emphasis (US Department of Health and Human Services [DHHS],
2010). However, little research has empirically examined how the effects of such message
execution factors can be influenced by consumer characteristics (Davis, 2010; Macias et al.,
2007; Sheehan, 2007). This limitation in the literature poses a necessity to investigate how the
risk disclosure prominence effects on consumer response to the DTC ad can be affected by
individual differences in consumer characteristics. That is, understanding in which situations the
effects could be enhanced or diluted, and in what mechanisms the effects operate remain as
understudied areas.
Furthermore, the direct effects of consumer characteristics on consumer response to the
DTC ad have also been rarely examined. To address this void in the DTCA literature, the current
research addresses the direct effects of DTCA regulatory knowledge, its moderating role of the
risk disclosure prominence effects, along with the direct effects of risk disclosure prominence on
consumer response to the DTC ad. To do so, the current research borrows from the persuasion
knowledge model (PKM) to conceptualize the direct and moderating influences of DTCA
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regulatory knowledge, and draws on the FDA’s (2009) conceptualization of risk disclosure
prominence to test the effects of varying levels of risk disclosure prominence.
Although a body of DTCA research has examined the content of DTC ads in terms of fair
balance between benefit and risk information, most of the studies have exclusively relied on
descriptive content analysis to determine the relative quantity of risk information compared to
benefit information (Davis, 2010; Davis & Meader, 2009; Huh & Cude, 2004; Macias et al.,
2007, 2010). However, to better understand the dynamic consumer information processing of
DTCA risk disclosure, one needs to examine under which conditions consumers could benefit
from risk disclosure provision more or less (Harker & Harker, 2007).
Research has rarely examined how consumer’s cognitive factors affect their information
processing of risk disclosure. Consumers’ knowledge of the FDA’s regulatory role for DTCA
may be one critical variable that has not been explored in terms of consumers’ DTCA risk
disclosure coping strategies. Given that it has been well-documented that consumers’ cognitive
structure such as marketplace knowledge or beliefs may exert considerable influence on
consumers’ persuasive message coping strategies (Boush, Friestad, & Wright, 2009; Friestad &
Wright, 1994; Obermiller & Spangenberg, 1998; Obermiller, Spangenberg, & MacLachlan,
2005), the lack of research addressing this perspective in the DTCA literature is undesirable.
Additionally, little research has explored a psychological mechanism whereby DTCA
regulatory knowledge, DTCA risk disclosure prominence, and their interplay may influence
recall and recognition of risk information. Although we know that in general enhanced cognitive
fluency may improve information processing outcomes (e.g., Alba & Hutchinson, 1987; Kardes,
Posavac, & Cronley, 2004; Lynch & Srull, 1982), a theory-driven research should provide
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convincing evidence regarding the process in the DTCA context. By revealing the black box in
consumers’ risk disclosure processing mechanism, those involved in DTCA will benefit from the
current study’s findings.

Purpose of the Study
The prescription drug industry is considered a high consequence area that affects public
health considerably. A number of consumer researchers have voiced that the examination of
DTCA impact on consumers should be based on observation of consumers' actual response to
DTCA (e.g., Beltramini, 2010; Hoek, Gendall, Rapson, & Louviere, 2011; Kavadas, Katsanis, &
LeBel, 2007; Myers, Royne, & Deitz, 2011). Such consumer-oriented approach will provide
insight into how to better encourage consumers to process information about the benefits and
risks of the drug in a balanced manner. Further, the approach will offer useful guidance for the
development of effective risk disclosure communication and consumer education program by the
FDA and pharmaceutical marketers, which have been underexplored in the literature.
From consumer education and public health perspectives, effective health risk
information provision through DTCA has an important implication. Considering that consumers'
sound health decisions hinge largely upon their appropriate use of health information, the current
research will elucidate how risk disclosure in DTCA can be more effectively presented in order
to enhance consumers’ cognitive memory performance regarding risk information in the ad.
It is worth noting that, during the last decades, the FDA’s DTCA public policy has
shifted its focus from DTCA content per se to consumers’ actual perception about the promoted
medicine (Davis & Meader, 2009; FDA, 2009). Despite a line of research on DTCA that has
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examined consumer perception such as general attitudes toward DTCA (e.g., Sumpradit,
Ascione, & Bagozzi, 2004) and preferences for communicating risk information (Davis, 2007),
how consumers’ cognitive knowledge structure can affect the dynamic mechanism of risk
disclosure coping strategies has received little research attention to date. By addressing this gap
in the literature, consumer educators, pharmaceutical marketers, and health communication
researchers will benefit from the current research’s findings.
Specifically, the current research attempts to examine the effects of consumer knowledge
of the FDA’s regulatory role for DTCA (hereinafter, DTCA regulatory knowledge), risk
disclosure prominence, and their interplay on consumer response to the DTC ad, including
perceived attention to, recall, and recognition of risk information in the DTC ad. Based on the
PKM perspective, DTCA regulatory knowledge is viewed as one type of crucial pharmaceutical
marketplace belief. Depending on varying levels of DTCA regulatory knowledge, consumers’
risk information processing outcomes using DTCA may largely vary.
The additional purpose of the present study is to investigate how the effects of DTCA
regulatory knowledge, risk disclosure prominence, and their interaction on consumers’ memory
of the drug’s potential health risks presented in the ad are mediated by perceived attention to risk
information in the ad. Considering that perceived attention represents one type of proxy measure
for consumer attention, perceived ease with locating disclosure in DTCA is expected to mediate
the effects of DTCA regulatory knowledge, disclosure prominence, and their interaction on
consumers’ cognitive memory performance, including the extent of recall and recognition of
health risk information (Bettman, Payne, & Staelin, 1986). Illuminating this under-examined
area will inform how risk disclosure in DTCA should be presented to enhance consumer benefit,
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and how consumers’ marketplace persuasion knowledge can contribute to public health.

The Organization of Dissertation
This dissertation is organized as follows. The next chapter presents a brief introduction to
the DTCA context. The chapter introduces the controversy over DTCA and the DTCA market in
the US context. Then, previous research on DTCA and the fair balance requirement with a focus
on risk disclosure are reviewed in order to provide a foundation for the research phenomenon of
this dissertation.
The next section addresses the importance of examining consumer information
processing in regard to DTCA risk disclosure. In the same chapter, based on the review of
literature, the research framework of this dissertation is introduced for examining DTCA
regulatory knowledge as a consumer factor and DTCA risk disclosure prominence as a messageside factor. In addition, the interactive relationship between DTCA regulatory knowledge and
risk disclosure prominence is addressed, along with the mediating role of perceived attention. By
doing so, this chapter extends prior research on DTCA risk disclosure and the PKM perspective.
Then, this chapter elaborates more on the FDA’s conceptualization of risk disclosure prominence
in DTCA to operationalize prominence in the experiment of current research. Based on the
review of literature, this chapter develops the research hypotheses.
The third chapter addresses the method of this research with justification. Using an
experimental approach, risk disclosure prominence is manipulated and tested as an independent
variable, and DTCA regulatory knowledge is measured and tested as not only an independent
variable but also a moderator of the prominence effects on consumer response to the ad.
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Criterion variables’ measures of this research include consumers’ perceived attention to, recall
of, and recognition of risk information. Perceived attention is conceptualized and measured as a
self-reported indicator to represent a proxy measure of consumers’ subjective attention. Recall
and recognition are measured to assess objective cognitive task performance to complement the
subjective self-report measure. Finally, potential covariates of the criterion variables are
identified from the health communication literature and controlled to exclude potential
confounding influences on the outcome variables.
The fourth chapter provides information about the analytical approach with justification
and the findings of this research. In this chapter, a set of multiple hierarchical regressions are
employed to test the main effects of DTCA regulatory knowledge and risk disclosure
prominence along with their interactive effects, as developed in the literature review chapter. In
addition, adopting a widely utilized approach to pinpoint the interaction pattern for regression
equations, the slopes and intercepts of the regression equations (for each subgroup: high and low
prominence) of this research are interpreted to see if the interactive patterns between DTCA
regulatory knowledge and risk disclosure prominence are consistent with the hypothesized ones.
Finally, a bootstrap approach, a contemporary method for mediation analysis, is employed to
examine the hypothesized mediating role of perceived attention.
The fifth chapter draws upon the results and discusses meaningful findings regarding the
effects of DTCA regulatory knowledge, risk disclosure prominence, their interaction, and the
mediating effects of perceived attention. The theoretical, managerial, and consumer
education/public health implications of the research are addressed. The final chapter addresses
the limitations of the study and suggests avenues for future research.
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CHAPTER 2: LITERATURE REVIEW
The DTCA Market
DTCA refers to the prescription drug ads that are published in magazines and newspapers
distributed to general consumers, and electronic media such as TV, radio, and the Internet are
also considered important platforms for DTCA (FDA, 2014a). Since the early 1990s when some
drug manufacturers began targeting consumers, DTCA has been one of the most widely utilized
health information sources (FDA, 2014a). In particular, after the restrictions on the DTCA
regulations were relaxed in 1997, its marketing expenditure has rapidly increased to be the
second largest consumer advertising category during the period of 2007-2008 (Nielsen, 2009).
More specifically, the DTCA spending of TV, radio, magazines, newspapers, and
outdoor, reached $4.9 billion in 2007 (Hilsenrath, 2011). Although it decreased to $4.3 billion in
2009 (Kaiser Family Foundation, 2010), to $4.0 billion in 2010, and to $3.9 billion in 2011 (IMS
Health, 2011), after the severe US economic recession of 2007-2008, the recent DTCA
expenditure reportedly turned to increase again. Further, when considering the growth potential
of Internet and mobile media DTCA, this advertising category will continue to grow for the
meantime. As a matter of fact, pharmaceutical marketers are increasingly embracing the Internet
as a promotional medium (Dutta-Bergman, 2004; Wymer, 2010). Online DTCA expenditure
alone is estimated to reach $1.3 billion by 2008 (Oser, 2006).
Today, the average American TV viewer watches as many as nine drug ads a day and
approximately 91% of Americans report that they are aware of the DTCA category (Myers,
Royne, & Deitz, 2011; Ventola, 2011). In the same token, those who watch average amounts of
TV are estimated to view approximately 30 hours of DTCA annually (An, 2007; Avery,
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Eisenberg, & Simon, 2012). Overall, given its amount of advertising spending and consumer
exposure to it, DTCA is considered a major consumer advertising category in the US consumer
media market (An & Muturi, 2011; Matear & Dacin, 2010; Royne & Myers, 2008; Tsai &
Lancaster, 2012; van de Pol & de Bakker, 2010).

The Context of DTCA
The early DTCA appeared in the US mass media in the 1980s though it has become a
popular promotional tool since the early 1990s (FDA, 2014a). At first, it was almost impossible
for pharmaceutical advertisers to meet the FDA’s strict requirements for information provision
due to the limitations of time in broadcast media, and therefore DTCA has been rarely
implemented in electronic media until the FDA’s relaxation of its regulations over DTCA in
television in 1997 (An & Kang, 2011).
Only two countries in the world allow DTCA due to its potential harmful consequences
on public health (Royne & Meyer, 2008): the US and New Zealand. In the US, prescription drug
advertising was allowed only to health care professionals in the past, based on the belief that the
general public would be less capable of understanding information about the uses and risks of
medical remedies (Macias & Lewis, 2004). However, the contemporary healthcare system and
communities have shifted to encourage the partnership between patients and health professionals
(Almond, 2001; Tomes, 2006). One of the drivers of this change may include consumers’
increased motivation for seeking health information and well-being. In addition, due to the
advance of media technologies including the Internet and portable communication devices,
consumers now have more access to various health information sources than ever before. In this
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context, DTCA is considered one of such important health information sources.
Over the past few decades, however, DTCA has raised a severe controversy among its
stakeholders. The proponents and opponents of DTCA have insisted on their own point of views,
and research findings regarding the influence of DTCA on consumers remain mixed (Royne &
Myers, 2008). DTCA proponents maintain that DTCA appears to drive conversation about
possible medical treatment options between the patient and their physician (Auton, 2007) as well
as remind the patient who already has been prescribed medicines to take them. From the
proponents’ perspective, DTCA is expected to provide current and potential patients with useful
health information that help them make informed health decisions (Royne & Myers, 2008).
Another alleged contribution of DTCA to public health is its capability to help people
recognize whether they may contract a certain disease that would otherwise remain unidentified
and untreated (Donohue & Berndt, 2004; Peyrot, Alperstein, Van Doren, & Poli, 1998; Roth,
1996). Advocates also argue that DTCA empowers patients to take a more active role in their
health care management (Holmer, 1999) and reduces the stigma associated with treatment of
certain health conditions such as clinical depression (An & Kang, 2011). Overall, proponents’
contention can be summarized as DTCA’s educational contribution to informed health decisions
and public health promotion in the long run (An & Muturi, 2011; Royne & Myers, 2008).
Advocates also point out that excessive regulations on DTCA may violate the freedom of speech
clause in the First Amendment (Grenard, Uy, Pagan, & Frosch, 2011).
In contrast, opponents maintain that DTCA tends to drive consumers’ unnecessary use of
medicines and urge them to spend on expensive branded drugs while steering them away from
generics that are equally or less-expensive (An & Muturi, 2011). Opponents also criticize that the
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relationship between the patient and their physician may deteriorates due to DTCA’s prompting
of patients’ disobedience and inappropriate prescription request (Rosenthal & Donohue, 2005).
In this regard, physicians have expressed a concern that patients’ inappropriate prescription
request often disturbs physician-patient conversation because they need to spend much time
correcting consumers’ misunderstanding obtained from DTCA (Harker & Harker, 2007; Royne
& Myers, 2008). Moreover, dissenters assert that information conveyed in DTC ads may confuse
vulnerable people and seek drug promotion rather than educating consumers about important
health issues (Royne & Myers, 2008; Tsai & Lancaster, 2012; Wolfe, 2002). Given these
concerns about the advertising category, critics have voiced that DTCA possibly leads to an
over-medicalized society that relates to an increase in the overall health care cost in society as a
whole (Beltramini, 2010; Parker & Pettijohn, 2003).
However, DTCA has already been allowed in the US. Despite the heated debate over the
advertising category, considering both positive and negative aspects of DTCA, researchers need
to examine how this advertising category may contribute to public health better. An alternative
discourse of the debate would be on seeking knowledge on how to promote the public’s
informed health decision through providing accurate and balanced health information and
encouraging consumers to process them adequately. If essential health information can be
effectively conveyed to and attended by consumers, this advertising category may successfully
serve public health education goals. In this regard, research on how consumer characteristics
can affect DTCA message coping strategies is a critical initiative.
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Previous Research on DTCA
A line of research has examined the content of DTCA. For instance, Sheehan (2007)
found that in a majority of branded prescription drug websites, the presentation of risk
information was significantly subordinate to that of promotional information. Hoek, Gendall, and
Freetham (2012) found that medical information overload may result in reduced consumer
comprehension. In this regard, Kaphingst et al., (2005) note that if consumers have a low level of
health literacy, misunderstanding of the drug’s uses and risks could occur. These studies imply
that the way of presenting health information in DTCA may affect consumers’ perception and
decision making.
In terms of message appeals employed in DTCA, Macias, Pashupati and Lewis (2007)
and Tsai and Lancaster (2012) found that most DTC ads employed both informational and
emotional appeals to a similar degree. However, they note that if advertisers use emotional
appeals more than informational appeals, it could make consumers’ attention stay away from
detailed drug attribute information (Tsai & Lancaster, 2012).
Another body of studies addressed consumer attitudes toward DTCA. Vatjanapukka and
Waryzak (2004) found that those who have been frequently exposed to DTC ads showed more
favorable attitudes toward the DTCA category. Women reported more favorable attitudes toward
DTCA (Robinson et al., 2004). In addition, senior Americans showed more favorable attitudes
toward DTCA than younger Americans (Williams & Hensel, 1995).
Recently, in response to the FDA’s interest in consumer perception (FDA, 2009),
research has examined various DTCA message strategies in terms of their effects on consumer
response to the ad. Bhutada, Cook, and Perri (2009) found that using reference to coupons in ads
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affect consumers’ evaluations of the ads. Shim, Cappella, and Leman (2010) also found that
presenting familiar health risks may improve consumer involvement with the ad. Ju and Park
(2013) examined the effects of numerical information in DTCA on consumers’ evaluations of the
ad and found that numerical drug information could enhance consumers’ perceived effectiveness
and attitudes toward the ad.
In sum, prior research could be categorized into four broad groups. First, one program of
research has examined the content of DTCA in terms of the relative proportion of benefit and
risk information. Second, message appeals have been a popular topic in the DTCA literature.
Third, general consumer attitudes toward DTCA have been examined. Finally and more recently,
research began to examine the effects of message strategies on consumers’ perception and
behavior regarding health issues.
However, despite this abundance of DTCA research, little research has explored how risk
disclosure presentation formats have consequences for consumer response to the ad, and how
individual differences in consumer characteristics influence such processes. Risk disclosure in
DTCA is required by the fair balance requirement (21 CFR 202.1) and examining the impact of
risk disclosure format represents an important research initiative. Nevertheless, since 2009 when
the FDA issued draft guidance of risk communication in DTCA, rare research has provided
empirical findings regarding various message execution factors outlined in the draft guidance,
while considering various consumer-side factors. To better understand the impact of DTCA on
consumers, more consumer-driven research is warranted.
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The Fair Balance Requirement of DTCA
The FFD&C Act (21 U.S.C. 352) requires pharmaceutical marketers to present any word,
statement, or other information in advertising prominently to render them to be read and
understood by the ordinary individual under customary conditions of purchase and use. In
particular, pharmaceutical manufacturers are obligated to provide important health risk
information conspicuously in their promotional materials (21 CFR 202.1). The provision of
important risk information in advertising is referred to as risk disclosure (or disclaimer) and its
major purpose is to offer consumers an opportunity to consider potential risks of the product
before purchase and use, and thereby help them make sound purchase decisions (Andrews,
Netmeyer, & Burton, 2009; Stewart & Martin, 2004).
In this regard, the fair balance requirement of benefit and risk information in DTCA has
received considerable research attention. A number of studies have examined whether
pharmaceutical advertisers comply with the requirement through examining the content of
DTCA (e.g., Huh & Cude, 2004; Kaphingst et al., 2004; Macias & Lewis, 2003; Macias et al.,
2007, 2010; Sheehan, 2007; Sumpradit et al., 2004). The FFD&C Act (21 U.S.C. 352) and
FDA’s regulations (21 CFR 202.1) clearly state that DTCA must present information about the
drug's effectiveness and risk in a fairly balanced manner in terms of content and format. In
particular, in its 2009 draft guidance for industry on the risk information presentation in
prescription drug promotion, the FDA provides specific guidelines for pharmaceutical
advertisers regarding how they can develop the content and format of DTCA to comply with the
FD&C Act. It is worth noting that the guidance provides a list of message execution factors that
the FDA considers when it reviews risk communication in DTCA.
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Importantly, the FDA (2009) points out that it views consumers’ net impression about the
drug as an important consideration when reviewing DTCA. This agency clearly indicates that its
concern about consumer impression draws on well-developed social science theories (FDA,
2009) and the concern is in alignment with the approach of other agencies such as the Federal
Trade Commission’s (FTC, 1984) policy statement on deception (103 F.T.C. 110, 174). For
instance, according to the FTC statement, advertising deception can be determined by examining
the overall consumer impression created by a certain advertising practice, claim, or
representation (103 F.T.C. 110, 174). In a similar vein, pharmaceutical industry members have
also conducted research and pointed out that the net impression shaped by the ad as a whole is an
important aspect to consider, independent of specific claims within the ad (PhRMA, 2009).
However, the majority of DTC ads tend to emphasize the benefits of the drug more
prominently than risks (Lexchin & Mintzes, 2002; Macias et al., 2007; Sheehan, 2007; Roth,
1996). A concern is whether the risk disclosure secures sufficient consumer attention to risk
information (Kopp & Bang, 2000). If an ad fails to present the disclosure with sufficient
prominence, the provision itself will not be effective for encouraging consumers to consider the
potential health risks of the drug use (Davis, 2010; Davis & Meader, 2009; Hoek et al., 2011).
In this regard, the FDA issues administrative letters (i.e., warning letters and untitled
letters) directly to the advertiser and publicize on the FDA’s website when an advertiser violates
the fair balance requirement. Among others, risk minimizing practices have been frequently cited
as one type of violation in the letters (Huh & Becker, 2005; Sheehan, 2003, 2007). Minimizing
drug risk is likely to result in consumers’ inappropriate prescription drug requests and uses.
Therefore, examining the effects of risk disclosure prominence on consumers’ perception may

16
offer invaluable insight.

Risk Disclosure in DTCA
Advertisers exert efforts to present their products and services in a favorable light in ads,
and thereby make them stand out among their competitors in a positive way (Eisend, 2006;
Kamins, Brand, Hoeke, & Moe, 1989). From the advertiser’s perspective, disclosing negative
aspects of brands may be less welcome (Franke, Huhmann, & Mothersbaugh, 2004; Hoek et al.,
2011; Kavadas et al., 2007). In line with this, researchers have noted that pharmaceutical
advertisers may be motivated to present serious health risks of the medicine inconspicuously,
while seeking to emphasize the benefits of it (e.g., Kavadas et al., 2007; Roth, 1996; Royne &
Myers, 2008; Morris & Millstein, 1984). As a matter of fact, research found that disclosing
health risks of drugs in DTC ads may result in unfavorable consumer response to the drug. For
instance, a higher ratio of risk information compared to the ratio of benefit information was more
likely to decrease consumers’ behavioral intentions to use the promoted drug (Kavadas et al.,
2007; Royne & Myers, 2008).
With regard to this, some consumer advertising categories have been required to present
important risk information associated with the use of products and services in their promotional
materials, a practice commonly named disclosures (or disclaimers) (Andrew et al., 2009). The
purpose of advertising disclosure is to clarify or qualify potentially misleading or deceptive
statements made within an ad (Hoy & Andrews, 2004).
Disclosures are a regulatory action to promote consumers’ complete understanding about
product attributes that may be integral to their decision making (Andrew et al., 2009; Stewart &
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Martin, 2004). Advertising disclosure can take on various forms including product claims, risks
of product usage, and information about reducing or avoiding risks (Stewart & Martin, 2004). In
light of this, DTCA risk disclosure typically provides information about important health risks,
side effects, and contraindications, associated with the use of prescription medicine.
Today, advertising disclosure became prevalent in the consumer information environment
(Andrews et al., 2009). The majority of consumers are aware of that disclosures are required by
law in certain product categories such health warnings in cigarette advertising (Eisend, 2006). In
this context, consumers should be able to utilize such disclaimers to make informed purchase
decisions (Foxman, Muehling, & Moore, 1988). Disclosures that are clearly and prominently
displayed can be effective for reducing misbeliefs and shaping attitudes and intentions (Hoy &
Stankey, 1993; Andrews et al., 2000; Wilkie, 1985). Furthermore, pharmaceutical advertisers can
be also protected from potential undue accusations of misleading or deceptive advertising,
assuming that the advertisers meet the risk disclosure requirements appropriately (Andrews et al.,
2000).
In the DTCA context, pharmaceutical advertisers are obligated to provide important
health risk information in DTC ads (21 CFR 202.1). However, to help prescription drug
consumers make sound prescription decisions, researchers need to understand how information
about health risks of the drug can be displayed more effectively. To do so, a consumer-oriented
research approach will provide insight into the development of more effective DTCA risk
communication. In addition, this approach also allows researchers to better understand the risk
disclosure processing mechanism from the consumer perspective. In the following section, the
literature on consumer information processing is reviewed with a focus on how DTCA risk
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disclosure prominence may help information processing.

Consumer Information Processing and DTCA Disclosure Prominence
Various advertising message strategies have been reported to result in varying consumer
responses to the ad (e.g., Lee et al., 2011a, 2011b; Liebermann & Flint-Goor, 1996). Extending
this view to DTCA risk disclosure processing, risk disclosure presentation strategies are likely to
affect consumers’ responses to the disclosure (Davis, 2010; Davis & Meader, 2009; Hoek et al.,
2011; Kavadas et al., 2007; Ju & Park, 2013). For instance, various message factors such as the
amount, emphasis, and specificity of messages will influence how risk disclosure is processed by
consumers (Kavadas et al., 2007; Morris, Ruffner, & Klimberg, 1985).
From a consumer information processing perspective, the success of risk disclosure
provision accrues to the extent that consumers notice, process, and comprehend such information
properly (Bettman & Kakkar, 1997; Bettmam, Payne, & Staelin, 1986; MacCarthy &
Mothersbaugh, 2002; MacInnis & Jaworskin, 1989; MacInnis, Moorman, & Jaworski, 1991). In
particular, to encourage consumers to pay sufficient attention to risk disclosure in advertising,
disclosures need to be displayed clearly and conspicuously (Hoy & Andrew, 2004).
This thought is reflected in the clear, conspicuous, and neutral (CCN) requirement added
to the amended FFD&C Act by the Food and Drug Administration Amendments Act of 2007
(DHHS, 2010). Although the amendment was targeted at DTC television or radio ads, the
principle is applicable across different DTCA practices in that it aims to improve risk
communication in DTCA in general. According to the CCN requirement, the major statement
relating to the side effects and contraindications of an advertised prescription drug must be
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presented in a clear, conspicuous, and neutral manner (DHHS, 2010).
The main purpose of the CCN requirement is to encourage DTC advertisers to present
potential health risk information in a more prominent manner to be easily attended and processed
by the consumer. In light of this, message strategies that promote consumers to easily pick out
and make use of such information are an important prerequisite for proper processing of DTCA
disclosures (Hoek et al., 2011).
In the same token, the FDA’s (2009) draft guidance of risk communication provides a
useful list of message execution factors that are expected to affect consumer processing of risk
disclosure, including overall location of risk disclosure, its font size, contrast, white space, etc.
No matter what execution devices are employed, if an ad fails to provide sufficient emphasis on
risk disclosure comparable with benefit information, it is considered a lack of fair balance (21
CFR 202.1(e)(7)(viii)).
Why does the prominence of DTCA risk disclosure matter? From an information
processing perspective, disclosures are critical communication tools and remedies when
consumers use potentially risky products or services (Andrews, 1998). Well-executed risk
disclosure provision can reduce inappropriate impression about promoted drug brands (Sheehan,
2007). Furthermore, disclosures can broaden consumers’ cognitive reference and thereby help
them avoid unrealistic generalization of the product’s efficacy (Andrews et al., 2000; Andrews et
al., 2009).
Andrews et al. (2009) summarize main cognitive functions of disclosures. Disclosures
allow consumers to access important risk information that is central to their decision making, and
therefore facilitate consumers’ retrieval of such information available in memory. In addition,
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disclosure can serve as a diagnostic reference point used for evaluating the ad claims. In the
same vein, disclosures can broaden the cognitive frame, and as a result reduce inappropriate
generalizations of the product’ efficacy. Based on this, disclosures may contribute to enhanced
accessibility, diagnosticity, and comprehension of advertising information (Andrews et al.,
2000).
Based on the literature, if disclosures are presented prominently in DTCA, consumer
processing performance will increase for information on the potential health risks of the drug.
Assuming that a major goal of DTCA disclosure is to educate consumers about important health
risks of the drug, risk disclosure prominence should be a critical research agenda to promote
consumers’ sound health decisions.

Cognitive Fluency and Risk Disclosure Processing
With regard to risk disclosure processing, consumers’ cognitive fluency represents an
important consideration. Consumer information processing is affected by a wide range of factors
and cognitive fluency has been known to play an important role (Bettman & Kakkar, 1977;
Bettman et al., 1986; Moorman, Diehl, Brinberg, & Kidwell, 2004). During the 1970s and 1980s,
a body of research attempted to examine the utility of information processing principles in
examining risk disclosure effects (e.g., Dyer & Shimp, 1977; Jacoby & Small, 1975; Wilkie &
Gardner, 1974). The studies suggested in common that effective disclosure programs need an
understanding of consumer information processing mechanisms (Mazis & Staelin, 1982). In this
regard, borrowing from information processing research will shed much light on understanding
the dynamic mechanism of DTCA disclosure processing.
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Hierarchy-of-effects communication models provide a theoretical foundation of the
current research. McGuire (1976) was one of frontiers who laid out the theoretical framework to
understand consumer information processing sequences. According to his framework, consumers
typically goes through a serious of sequences in acquiring, processing, and using information.
More specifically, the sequences have at least five folds: exposure, attention, comprehension,
retention/retrieval, and decision making (McGuire, 1976). Although these phases are not always
clearly distinct from each other or do not always go through this order, the framework serves as a
useful foundation for examining how consumer information processing operates and which
cognitive factors should be examined (Mazis & Staelin, 1982).
More importantly, the model suggests that there could be factors that enhance or impede
communication effectiveness. In light of the current research, an important information
processing phase may be attention. Attention measures serve as an important variable for the
early stages of information processing (Krugman, Fox, Fletcher, Fischer, & Rojas, 1994). It has
been well-documented that despite their limited cognitive capacity (Lynch & Srull, 1982; Mazis
& Staelin, 1982), today’s consumers are exposed to a vast amount of marketplace information
(Boush et al., 2009; Knowles & Linn, 2003). If advertisers fail to attract consumer attention to
important product attribute information, communication effectiveness will be significantly
decreased (Krugman et al., 1994).
Once consumers paid sufficient attention to information, consumers should be able to
retrieve the stored information, and more prominent information is more likely to be retrieved in
a decision making situation (Alba & Hutchinson, 1987; Lynch & Srull, 1982). When consumers
are exposed to information, it is transformed into consumers’ cognitive storage (i.e., memory), a
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process referred to as encoding. Prominence of information has been regarded as a factor that
enhances ease of encoding (Alba & Hutchinson, 1987; Lynch & Srull, 1982). That is, more
prominent events in the information environment are more likely to enhance consumer encoding
of information (Bettman et al, 1986). In this regard, Mazis and Staelin (1982) note that
information presented in a confusing manner is more difficult to encode and retrieve (i.e.,
decode). This line of studies suggests to examine the effects of prominence on consumers’
attention and memory.

The Influence of Cognitive Structure
To better understand the risk disclosure processing phenomenon, one needs to look to
consumer-side aspects as well as message-side factors. Mazis and Staelin (1982) note that
attention and information retention/retrieval are affected by both internal and external factors.
As noted, external factors may involve the characteristics of the message itself such as risk
disclosure prominence. On the other hand, internal factors may include consumer capacity and
motivation to process the information (Mazis & Staelin, 1982). In particular, cognitive structure
such as persuasion knowledge has been suggested as an important consideration in information
processing (Alba & Hutchinson, 1987; Friestad & Wright, 1994; Goodstein, 1993; Kardes et al.,
2004). In light of this, examining the interplay between internal and external factors may provide
invaluable insight into our understanding of consumers’ risk disclosure coping strategies.
Among others, the current research addresses DTCA regulatory knowledge to examine
how consumers’ category-based processing (Goodstein, 1993) affects their response to the DTC
ad. Consumer psychology indicates that preexisting category knowledge links consumers’
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expectations to their motivation to process and evaluate information stimuli (Sujan, 1985). This
category knowledge structure is referred to as schemata (Goodstein, 1993). Advertising schemas
are developed through repeated learning regarding a particular advertising category, and this can
involve semantic and structural features (Friestad & Wright, 1994). Based on the literature,
therefore, it is expected that consumers’ cognitive schemas regarding a particular regulatory
context for ad design (i.e., DTCA regulatory knowledge) can be organized around product
categories (Goodstein, 1993). In addition, individuals may have different levels of DTCA
regulatory knowledge because they may have varying levels of experience with DTCA.
Addressing the role of DTCA regulatory knowledge may shed light on how consumers cope with
DTCA information using their regulatory schema regarding the DTCA category, which is an
underexplored area.

DTCA Regulatory Knowledge and Risk Disclosure Prominence
The notion of information encoding (i.e., storing) and decoding (i.e., retrieving)
proficiency is often associated with preexisting memory structure (Bettman et al., 1986; Mazis &
Staelin, 1982). As noted, cognitive schemata involve how information is organized in a longterm memory regarding a particular category. DTCA regulatory knowledge may represent one
type of cognitive schemata regarding the DTCA category. This knowledge can include overall
understanding of FDA’s overall control over DTCA, particularly its content and design, and
developmental and approval process. In addition, textual schemata relate the extent to which
consumers are familiar with a particular way of information presentation in a particular
information category (Bettman et al., 1986; Sheehan, 2007). Given that consumers are socialized
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to learn about how DTCA tends to present information about the medicine (i.e., headline, uses
and efficacy information, and risk disclosure) and how such information is regulated by law, the
overall heuristic based on type regulatory and textual schemata regarding DTCA serves as
cognitive processing facilitators. That is, information organization that is compatible with
consuimers’ pre-existing schemata would be more easily recognized and therefore effective
(Sheehan, 2007). Although Sheehan (2007) notes that textual schemata would facilitate
consumer information processing from DTCA, given the unique regulatory context of DTCA for
ad design, examining the interactive influence of textual and regulatory schemata could provide
richer insight into our understanding of risk disclosure effects.
In this regard, consumers are more likely to view that important information is
highlighted using various message execution devices such as color, font, size, or location. The
risk disclosure prominence effects could be a result of consumers’ textual schemata. On the other
hand, those who have high DTCA regulatory knowledge may recognize the advertising category
must present important risk information and are more likely to look to risk disclosure to make
sound health decisions regardless of textual devices. Based on this, DTCA regulatory knowledge
could serve as heuristic inference cues and will signal consumers’ locating of risk disclosure
information in DTC ads. When DTCA regulatory knowledge is high, consumers’ diagnocity of
risk information in DTC ads will be high, and such enhanced diagnocity is more likely to
improve cognitive performance regarding locating and memorizing information (Kardes et al.,
2004).
On the other hand, DTCA regulatory knowledge, as consumer marketplace persuasion
knowledge, will moderate the risk disclosure prominence effects because individuals will have
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varying levels of DTCA regulatory knowledge. Among those with high DTCA regulatory
knowledge, their superior regulatory and textual schemata regarding risk disclosure presentation
will lead to improved search selectivity and memory of risk information, whereas among those
with low DTCA regulatory knowledge, varying levels of risk disclosure prominence plays a
more important role as peripheral signals or cues (Petty & Cacioppo, 1986) and consumers are
more likely to activate their general textual schemata dominantly than regulatory schemata. That
is, more prominent risk disclosure is more likely to provoke enhanced search selectivity and
thereby improved memory of information. Put differently, among less knowledgeable
individuals, a heuristic cognitive path for textual schemata will prevail, such that more prominent
disclosure will be easily detected and utilized, whereas less prominent disclosure will be less
attended and memorized. Based on the foregoing review of literature, examining the role of
DTCA regulatory knowledge will illuminate how consumers’ knowledge about the DTCA’s
regulatory context may improve their DTCA health risk information coping strategies.

The Framework of Dissertation
Conceptualization of Risk Disclosure Prominence in the Literature
It has long been documented that a wide range of advertising message factors affect
consumer perception and behavior (e.g., Jackson, 1992; Liebermann & Flint-Goor, 1996;
O’Keefe, 2002, 2003; Taylor, 1999). A number of studies have examined whether vivid
messages are more effective than non-vivid messages (e.g., Collins, Taylor, Wood, &
Thompson, 1988; Frey & Eagly, 1993; Taylor & Thompson, 1982). The literature on message
presentation strategies shows that various advertising execution factors can influence consumer
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motivation and ability to process information, including message specificity (Morris & Millstein,
1984), the amount of information (Tucker & Smith, 1987), the emphasis of risk information
(Morris, Ruffner, and Klimberg, 1985), and the completeness of risk information (Davis, 2000).
Andrews (1998) notes that these “message factors can play a pivotal role in the processing of
disclosure information by consumers” (p. 1). Based on the literature, varying levels of risk
disclosure prominence can lead to different communication effects.
There could be various approaches to conceptualize message prominence. For instance,
the location of the message in an ad may affect consumer perception about the ad (Crowley &
Hoyer, 1994; Haugtvedt & Wegener, 1994). Pieters, Rosenbergen, and Hartog’s (1996) eyetracking study found that subjects processed ad headline first, followed by body copy visual
among others. This finding implies that information in the top portion of the ad may be more
likely to attract viewers' attention than other information elements in the ad (Royne & Myers,
2008). However, Main, Argo, and Buhman (2004) examined print DTC ads and found that risk
information was typically presented at the bottom of the ads. In this case, because the relegated
risk disclosure is less noticeable, consumer decision making will be based exclusively on
information about drug efficacy that is typically presented in a more noticeable portion of ads.
In the context of DTCA risk disclosure, if consumers pay attention exclusively to the
medicine’s efficacy, they are more likely to dismiss risk information that is central to informed
health decisions. Considering that consumers typically do not pay much attention to risk
information at the bottom of the DTC ad, the risk disclosure effectiveness will largely hinge on
its prominence.
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The FDA’s Conceptualization of Risk Disclosure Prominence in DTCA
It is worth noting how the FDA conceptualizes risk disclosure prominence and guides
pharmaceutical advertisers regarding the development of DTCA risk communication. The FDA
(2009) conceptualizes that disclosure prominence could consist of various message execution
variables rather than a particular message implementing factor. The agency pays attention to
consumers’ net impression as a whole (FDA, 2009). For instance, if a DTC ad presents risk
disclosure in smaller, non-bolded font without sufficient surrounding white space, while benefit
information is presented in larger bolded font with abundant surrounding white space, this
practice may be regarded as risk-minimizing or potentially misleading (FDA, 2009).
This conceptualization is well represented in the FDA’s administrative letters (i.e.,
warning or untitled letters) explaining pharmaceutical advertisers’ violations of the fair balance
requirement. These letters signal to the advertisers their violative promotional practices and
advise them to release corrective advertising if needed (FDA, 2009). During the period of 19972001 the FDA issued between 15 and 25 letters per year, citing DTC promotional materials (US
Government Accountability Office; GAO, 2008). From 1997 to 2002, the FDA issued 99
administrative letters (Sheehan, 2003). In addition, from 2002 to 2005, the agency issued
between 8 and 11 regulatory letters per year that cited DTC promotional materials (GAO, 2008).
Although the GAO points out that the overall number of letters per year has continued to decline,
given that the 2002 policy change lengthened the agency’s process for issuing letters, it is hard to
judge whether pharmaceutical advertisers’ misleading or risk-minimizing DTCA practices have
continuously decreased. Rather, the GAO (2006, 2008) recommends that the FDA improves their
oversight of DTA, by establishing a complete and systematic process for tracking and
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prioritizing all materials that the agency receives for review.
Among various problematic DTCA practices, a number of letters state that the
promotional materials for prescription drugs employed message techniques that are likely to
minimize consumers’ risk perception about the medicine through a wide range of message
presentation formats (Sheehan, 2003). More importantly, even when the ads presented required
risk information, they appeared to fail to provide sufficient prominence of risk disclosure
comparable with that of benefit information (Sheehan, 2003). This is undesirable given that
imbalanced emphasis on benefit information is likely to relate to unrealistic perception about the
medicine’s efficacy, while leading consumers to disregard potential health risks of the drug (An
& Muturi, 2011). To address this public health concern, the current research builds on the FDA’s
conceptualization of risk disclosure prominence and operationalizes disclosure prominence as a
combination of various message factors that are selected from the FDA’s (2009) draft guidance
of DTCA risk communication.
To be more specific, the FDA (2009) lays out major risk minimizing message techniques
in their draft guidance, titled “Presenting Risk Information in Prescription Drug and Medical
Device Promotion.” This guidance states that promotional materials are misleading if they fail to
present information about risks associated with a drug with a prominence reasonably comparable
to the presentation of information related to the effectiveness of the drug.
In particular, the FDA takes into account “all implementing factors such as typography,
layout, contrast, headlines, paragraphing, white space, and any other techniques apt to achieve
emphasis" (21 CFR 202.1(e)(7)(viii)). To encourage consumers to make informed prescription
decisions, it is critical to make consumers pay sufficient attention to risk disclosure as well as
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information about the drug’s efficacy or uses. Further, the information should be properly
recalled or recognized in their decision making situations. Depending on how advertisers use the
above message techniques to present risk disclosure, prominence can be differently
operationalized. In this research, two levels of disclosure prominence is operationalized to
represent high and low prominence, using the techniques outlined by the FDA (2009).
In sum, the Code of Federal Regulation (21 CFR 202.1) and the FDA’s draft guidance for
prescription drug promotion (FDA, 2009) clearly document how risk information as well as
benefit information can be developed to be noticeable so that consumers are able to pay
sufficient attention to both information with similar ease. Based on the foregoing discussion, in
the following section the theoretical background and operationalization of DTCA risk disclosure
prominence are addressed.

The Study
Risk Disclosure Prominence as a Message Factor (Main Effects)
To secure intended risk disclosure effectiveness, DTCA designers should consider
persuasion sequences including exposure, processing, and action (Bettman et al., 1986;
Wogalter, Conzola, & Smith-Jackson, 2002). In particular, as to advertising execution factors,
DTCA researchers have paid attention to the exposure stage because attracting consumers’
attention to risk disclosure is the first step for effective advertising campaigns (Hoek et al.,
2011).
A couple of theoretical perspectives on consumer information processing provide
convincing explanations regarding the importance of risk disclosure prominence. First of all,
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selective attention research suggests that human information processing capacity has limitations
and therefore consumers tend to select and focus more on particular portion of the message at a
time (e.g., Bettman et al., 1986; Lavie, 2001; Mayer & Moreno, 2003; Miller, 1994; Paas, Renkl,
& Sweller, 2004).
Regarding DTCA, these cognitive limitations are more likely to be found. Compared with
health professionals, novice consumers will have limited medical knowledge. For this reason,
negative medical information presented less prominently is more likely to result in information
avoidance. In general, prescription drug advertising presents more difficult medical information
compared with over-the-counter (OTC) drugs (Andrews, 1998). Based on this, less
knowledgeable consumers are more likely to selectively attend particular information in the DTC
ad to reduce cognitive overload (Alba & Hutchinson, 1987).
This implies that information that causes cognitive overload in DTCA may result in
biased net impression about the medicine (Hoek et al., 2011). To ordinary consumers, less
prominent risk disclosure is likely to cause cognitive fatigue because it requires consumers to
exert more efforts to find and focus on the less legible messages (Davis, 2010). More prominent
disclosure could encourage less knowledgeable consumers to closely scrutinize DTCA risk
information (Wilkie, 1986).
Depending on risk disclosure prominence, ease of processing may vary. This study
examines perceived attention as a proxy measure of objective attention. As cognitive fluency is
likely to be affected by prominence (e.g., Hyönä & Lorch, 2004; Lorch, Lorch, & Inman, 1993;
Loman & Mayer, 1983; Spyridakis & Standal, 1987), perceived attention to risk disclosure will
be also increased by high prominence. Further, perceived attention will lead to increased recall
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and recognition performance. In this regard, this research addresses risk disclosure prominence
as an important message factor regarding consumers’ informed prescription decision making.
Operationalization of Risk Disclosure Prominence
A couple of typographical devices are utilized to operaionalize risk disclosure
prominence of DTCA. Those factors include text color, title, font size, bold texts, box outline,
and location based on the FDA’s (2009) risk communication draft guidance. To be more specific,
to manipulate the risk disclosure prominence, this research employs a couple of attention
signaling cues. Signaling can be defined as the use of typographical devices designed to
highlight aspects of a text’s structure or content without altering the information in the ad (Lorch
et al., 1993).
Among others, most widely employed signaling devices may include headlines or
subheads (Hyönä & Lorch, 2004). The FDA (2009) requires that pharmaceutical promotional
materials use appropriate typographical signals consistently across benefit and risk information
to foster accurate and non-misleading impressions about the drug. Furthermore, the literature
suggests that product warnings need to employ vivid colors and noticeable font sizes, and use
any symbols to summarize and reinforce key warning details, which would help consumers
easily locate risk information (Bettman et al., 1986).
In a similar vein, Argo and Main (2004) conducted a meta-analysis and found that vivid
color such as red enhances consumer attention to risk information. In addition, physical location
of risk information may affect message prominence (Hoek et al., 2011). For instance, risk
information close to benefit information was found to be more noticeable than risk information
near the bottom of a print ad (Torres, Sierra, & Heiser, 2007). Texts with frame lines were also
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found to be superior to texts without outlines in leading attention to information and retaining
memory for short periods (Bettman et al., 1986; Hoek et al., 2011; Wogalter et al., 2002;
Wogalter & Shaver, 2001).
In this dissertation, based on the FDA’s (2009) draft guidance, the previous literature on
risk disclosure presentation, and the preliminary analysis of hundreds of DTC ads, the attentionenhancing factors were selected, including the use of cueing signals (i.e., bullet points, bold
texts, capitalized first words), use of color (i.e., red), boxed frame lines, larger font sizes, and
position of texts (i.e., close to use and benefit information vs. bottom of the ad). In contrast, the
less prominence condition is manipulated as disclosures using no bullet points, no bold texts, no
capitalization of first words, no red color, no box lines, smaller font sizes, and relegation toward
the bottom of the ad page.

Research Hypotheses
Perceived Attention to Risk Disclosure
Researchers consider attention an important cognitive process that affects consumers’
decision making outcomes (Lynch & Srull, 1982). However, it is worthy to note selective aspects
of attention. Regarding risk disclosure, physically salient information in the environment is more
likely to capture a disproportionate amount of attention (Taylor & Fiske, 1978). Given this,
consumers’ attention to DTCA risk disclosure may play a role in leading them to discuss the
risks of taking the drug with their doctors (Menon, Deshpande, Perri III, & Zinkhan, 2003).
More specifically, in the context of risk communication in advertising, attention has been
noted as an important early stage of hierarchy-of-effects communication models (Krugman et al,
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1994). Although risk disclosure has become a common phenomenon in the contemporary
information environment (Mazis, Morris, & Swasy, 1991), surprisingly few empirical studies
have assessed its effectiveness in the DTCA context. Advertising research has reported that mere
advertising exposure itself is not always effective for promoting intended consumer response to
the ad (Goodrich, 2011). Consumer attention to ad information needs to be secured and different
ad stimuli (e.g., ad type, ad location, and page type) can affect varying attention levels
(Goodrich, 2011).
There could be various ways to conceptualize and measure attention (i.e., behavior
observation, psychophysiology, and self-reports), and each approach has their own
methodological pros and cons (Reeves & Thorson, 1986; Thorson, Chi, & Leavitt, 1992). One of
the commonly employed measurement approaches to attention is introspective self-observation
(i.e., self-reported) (Chaffee & Schleuder, 1986). In particular, given that more often than not
resources and instruments for objective measures of attention are not available to researchers, the
simplest and available way to assess attention is self-reports (Reeves & Thorson, 1986; Thorson
et al., 1992), referred to as perceived attention or self-reported weight of watching. In this regard,
despite criticism that perceived attention has limitations for measuring actual attention, as an
alternative proxy measure of attention, researchers have often employed the subjective measure
(e.g., Thorson et al., 1992).
The use of self-reported perceived attention can be justified from the cognitive inference
literature. Although consumers’ self-beliefs about a particular phenomenon is seldom complete
or errorless, consumer research on meta-knowledge has found that their subjective or perceived
judgment plays an important role in cognitive inference processes (Alba & Hutchinson, 2000).
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This has been often labeled as cognitive heuristics (Kardes et al., 2004). Therefore, although
perceived attention measure cannot represent an ideal approach to assessing objective attention,
the utility of it has been acknowledged (e.g., Reeves & Thorson, 1986; Chaffee & Schleuder,
1986; Thorson et al., 1992). In particular, Chaffee and Schleuder (1986) note that the subjective
attention measures are notable for their utility and general validity than for their reliability and
precision. Given the literature, with rigorous theoretical underpinning and careful caution in
interpreting the research findings, perceived attention measure, as a proxy measurement
approach, can provide consumer researchers with usability to better understand the phenomenon
of consumer attention to advertising. Further, if the researcher employ other theoretically
relevant construct measures simultaneously, the construct (e.g., convergence validity) validity or
criterion validity (e.g., predictive validity) can be assessed. Based on the consideration of these
various methodological issues and limitations, the current research in that regard employs a selfreported perceived attention measure (see the method section for more information).
Taken together, for consumers to make sound prescription decisions, risk disclosure
information should be attended so that they can utilize the information reasonably. Prominent
risk disclosure in a DTC ad may prime important product attributes such as potential health risks,
adverse reactions, and contraindications, and thereby make risk information more accessible
from memory (Menon et al., 2003a). Varying levels of risk disclosure prominence are predicted
to result in disproportional levels of attention. Higher prominence disclosure are more likely to
lead to higher consumer attention to risk disclosure than lower prominence disclosure. Based on
the review of literature on prominence and attention, the following hypothesis can be raised:
H1: Higher risk disclosure prominence will lead to greater perceived attention to
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risk disclosure.

Recall and Recognition of Risk Disclosure
Advertising exposure has an impact on consumers’ recall and recognition (Okechuku,
1992; Pechmann & Stewart, 1990; Rosbergen, Pieters, & Wedel, 1997; Shapiro & Krishnan,
2001). Although these two cognitive measures have been widely employed in the advertising
literature, the measures of recall are often criticized because they may underestimate advertising
effectiveness under low levels of cognitive elaboration conditions (Petty et al., 1983). In general,
a recall test involves a situation where a subject must independently retrieve previously acquired
information (e.g., subjects are asked to list all product attributes learned from an ad). On the
other hand, in a recognition test, subjects are given a list of choices and must indicate which one
was previously presented in the ad. However, Due to the different cognitive task difficulties
between the two methodological approaches, in general recall score is reported as lower than
recognition score (Lynch & Srull, 1982), implying that statistical variations in recall tests might
be minimal. Nevertheless, the use of recall measure for advertising effectiveness can represent
the levels of cognitive elaboration devoted to processing information, indicating active cognitive
processing (Lord & Burnkrant, 1993).
Given the advantages and disadvantages of the two memory measures, cognitive
psychology suggests that one of the most simple and parsimonious approach to measure
information retrievability takes a two-stage process, where subjects must independently retrieve
information (i.e., unaided recall) and then perform some recognition check on whether the item
was presented in a particular context (i.e., aided recognition), referred to as the generation-
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recognition theory (Lynch & Srull, 1982). Researchers are advised to employ recognition
measures to complement the limitations of the recall measure in advertising message research
(Okechuku, 1992). In this regard, the current research adopts the generation-recognition
approach to assess consumer risk information retrievability.
There are robust findings that information organization is important for memory
performance (Lynch & Srull, 1982). Some organizational formats may facilitate the retrieval
fluency and, therefore, information presentation formats are important for memory-based
judgments (Lynch & Srull, 1982). Greater attention to information is more likely to lead to
greater focus on product’s facts and objective attributes (Alba & Hutchinson, 1987; Lynch &
Srull, 1982; Okechuku, 1992; Park & Lessig, 1981) and such increased focus on information
may lead consumers to memorize more details of the information.
Therefore, when the consumer takes a memory test, more prominent risk disclosure will
lead to higher recall and recognition scores (Lynch & Srull, 1982). In the context of DTCA,
examining recall and recognition of the drug’s health risks may provide important educational
implications (e.g., Davis, 2010). Based on the literature, the following research hypotheses can
be raised:
H2: Higher risk disclosure prominence will lead to greater recall of health risk
information.
H3: Higher risk disclosure prominence will lead to greater recognition of health risk
information.
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DTCA Regulatory Knowledge as a Consumer Factor (Main Effects)
Another important factor that may affect DTCA risk disclosure processing in the current
research is consumers' individual differences in DTCA regulatory knowledge. Depending on
individuals' unique cognitive schema, their coping strategies of health information in DTCA will
vary. Consumer behavior models have described knowledge as an individual difference variable
affecting all phases of the decision process, especially information search (Beatty & Smith,
1987; Brucks, 1985; Moorman, Diehl, Brinberg, & Kidwell, 2004). A number of researchers
have examined the impact of knowledge on decision making (e.g., Alba & Hutchinson, 2000;
Ellen, 1994; House et al., 2004; Park, Mothersbaugh, & Feick, 1994). In the same token, the
PKM literature suggests that marketplace knowledge can affect consumer information processing
of marketing messages (Friestad & Wright, 1994). From the PKM perspective (Friestad &
Wright, 1994), DTCA regulatory knowledge can be viewed as one type of consumer marketplace
beliefs in the DTCA context. Knowledge about a particular advertising category is expected to
exert considerable influence on consumers’ information coping strategies (Boush et al., 2009;
Obermiller & Spangenberg, 1998) and therefore DTCA regulatory knowledge may affect DTCA
information coping strategies.
As noted, in contemporary marketplace, consumers face a huge amount of persuasive
messages and might have been socialized to develop certain beliefs or cognitive structure
regarding such influence attempts (Boush et al., 2009; Darke & Ritchie, 2007). In order to
protect their own interests, consumers employ such beliefs or cognitive structure in their
information processing, referred to as epistemic doubt, and act as reasonable consumers in the
market (Boush et al., 2009; Darke & Ritchie, 2007; Friestad & Wright, 1995, 1999). Given this,
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consumers’ use of DTCA risk disclosure may be affected by such cognitive structure.
Research on consumers’ knowledge of a product category has a long history in consumer
research due to its effects on consumers’ decision making process (Engel, Blackwell, & Miniard,
1990). Since Brucks (1985) described three categories of consumer knowledge including
subjective knowledge that is what the consumer thinks he or she knows, objective knowledge
that is measured by some type of test, and prior experience with the product category, many
scholars have examined this construct (e.g., Alba & Hutchinson, 1987; Flynn & Goldsmith,
1999). In addition, Peter, Olson, Grunert (1999) described that consumers have four levels of
product knowledge, including product class, product form, brands, and models.
However, given all this research attention, it is surprising that little research has
addressed the conceptualization and measurement of it in the context of DTCA. In particular,
despite attention on product category knowledge or issue knowledge, consumers’ cognitive
structure regarding a particular advertising category’s regulatory context has been largely
ignored in the DTCA literature. To better understand the impact of DTCA on consumers,
researchers should examine not only its message aspects, but relevant consumer aspects such as
individual differences in DTCA regulatory knowledge structure (Sheehan, 2007).
As part of a broader set of marketplace beliefs, the current research referred DTCA
regulatory knowledge to as “a set of cognitive structures about the FDA’s general control over
DTCA, the FDA’s involvement with DTCA content and design, the ad category’s developmental
and approval process, and the FDA’s involvement with DTCA research.” Despite a possibility to
conceptualize DTCA regulatory knowledge in different ways, given a dearth of prior research on
this construct in the DTCA literature, the current research will be the first step for further
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examination.
To develop a practical and valid measurement scale, this research adopts the measure
items of DTCA regulatory knowledge from the FDA’s (2014) current page for consumer health
education (i.e., For Consumers & Patients). This could have a couple of practical implications.
First, the items represent actual consumers’ curiosity about the DTCA category. Low knowledge
score could represent low levels of regulatory understanding for DTCA, whereas high
knowledge score could represent reasonable understanding of the advertising category’s
regulatory context. Second, the answer to each item reflects the FDA’s current thoughts and
regulations about the DTCA category. Therefore, employing those items will provide practical
insight into consumer education by the FDA and DTCA marketers.
In general, knowledge about an advertising category enables consumers “to recognize,
analyze, interpret, evaluate, and remember persuasion attempts and select and execute coping
tactics believed to be effective and appropriate” (Friestad & Wright, 1994, p. 3). Given this
presumed role of knowledge, consumers’ DTCA regulatory knowledge may serve as cognitive
reference points for DTCA risk disclosure coping strategies. Consumers may be more or less
motivated and/or able to process disclosures in DTCA, depending on varying levels of DTCA
regulatory knowledge, because risk disclosure is part of regulatory requirement by the FDA.
Research supports this theoretical prediction. In general, consumer responses to the ad are
affected by individual differences in consumers’ motivation and ability to process information
(Kavadas et al., 2007; Petty, Cacioppo, & Schumann, 1983). Research on systematic-heuristic
inference (Chaiken & Eagly, 1989) and elaborated likelihood model (ELM) (Petty & Cacioppo,
1986) provides plausible explanations; cognitively more capable and motivated individuals are

40
less affected by peripheral message factors such as information source (Petty et al., 1983) or
presentation formats (Artz & Tybout, 1999), whereas less capable and motivated individuals are
more affected by such factors.
In addition, through the notion of consumer expertise, Alba and Hutchinson (1987) argue
that higher consumer expertise tends to improve cognitive task performance regarding
complicated information processing that requires cognitive resources. More knowledgeable
consumers’ ability to process and utilize relevant information in decision making may be
superior to that of less knowledgeable ones (Alba & Hutchinson, 1987). The preceding review of
literature suggests the following research hypotheses:
H4: Higher DTCA regulatory knowledge will lead to greater perceived attention to
risk disclosure.
H5: Higher DTCA regulatory knowledge will lead to greater recall of health risk
information.
H6: Higher DTCA regulatory knowledge will lead to greater recognition of health
risk information.

DTCA Regulatory Knowledge as a Consumer Factor (Moderating Effects)
Further, DTCA regulatory knowledge is expected to moderate the risk disclosure
prominence effects. As has been discussed, individuals tend to select a more efficient cognitive
path to reduce cognitive overload (Bettman & Zins, 1979; Wright, 1975). Given this theoretical
premise, a concern is raised when DTCA presents disclosures in less prominent or less accessible
formats. In general, DTCA provides medical information that requires more cognitive efforts
(Macias et al., 2007; Royne & Myers, 2008). For instance, Sheehan (2006) examined the
language of DTCA to determine whether DTCA language is easy to read and understand. She
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found that DTCA ads are among the most difficult ads. In particular, processing information that
discusses the drug’s risks and contraindications is considered one of the most challenging
cognitive tasks to novice consumers (Sheehan, 2006). Considering this nature of DTCA risk
disclosure, more prominent risk disclosure provision will help low DTCA regulatory knowledge
consumers locate and utilize risk information more fluently, because such message format is
expected to reduce cognitive efforts required to process hard-to-read risk information whereby it
improves information search selectivity. In contrast, higher DTCA regulatory knowledge may
relate to higher cognitive capacity to search and utilize DTCA risk information, and therefore
higher DTCA regulatory knowledge consumers may better perform cognitive tasks regardless of
varying levels of risk disclosure prominence, indicating minimal prominence effects for higher
DTCA regulatory knowledge consumers.
Further supports for the moderating influence of DTCA regulatory knowledge on the risk
disclosure prominence effects can be found from the self-consistency hypothesis (Moorman et
al., 2004). In general, when consumers perceive themselves as knowledgeable about a particular
category, they are more likely to locate themselves proximate to information associated with that
knowledge (Moorman et al., 2004). Extending this, consumers who are more knowledgeable
about the FDA’s regulatory role for DTCA are more likely to be motivated and/or able to process
risk disclosure required by regulation, because those with high DTCA regulatory knowledge will
be more proficient with locating and utilizing risk disclosure in DTCA, referred to as high search
selectivity (Moornan et al., 2004). Put simply, higher DTCA regulatory knowledge is more likely
to be associated with higher search selectivity for risk disclosure in DTCA. This enhanced
cognitive fluency will enable more knowledgeable consumers to attend and memorize
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disclosures easily and therefore they will be less sensitive to risk disclosure prominence.
In contrast, as to low DTCA regulatory knowledge consumers, their limited cognitive
resources will result in more reliance on risk disclosure prominence to reduce their cognitive
burden required for locating and processing risk disclosure to improve cognitive efficiency.
When risk disclosure is presented more prominently, those with low DTCA regulatory
knowledge will be more capable of attending and memorizing risk information, whereas when
risk disclosure is presented less prominently, they will be less capable of locating and
memorizing risk information.
Taken together, DTCA regulatory knowledge may moderate the risk disclosure
prominence effects on consumer response to the ad. Those with low DTCA regulatory
knowledge may rely more on disclosure prominence, such that more prominent disclosures are
more likely to attract low knowledge consumers’ attention to risk disclosure, and thereby lead to
enhanced memory of health risk information, including recall and recognition. In contrast,
among high DTCA regulatory knowledge consumers, the prominence effects will be diluted,
because highly knowledgeable consumers’ search selectivity and memory performance will be
consistently high across varying levels of prominence. Therefore, the following hypothesis can
be raised:
H7: DTCA regulatory knowledge will moderate the risk disclosure prominence
effects on: (a) perceived attention to risk disclosure; (b) recall; and (c)
recognition of health risk information, such that low DTCA regulatory
knowledge consumers will show greater prominence effects, whereas high
DTCA regulatory knowledge consumers will show minimal prominence effects.
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The Mediating Role of Perceived Attention (Mediating Effects)
The foregoing sections address that certain formats and methods for presenting
information can affect consumers’ perceived ease with information processing. For this reason,
Bettman, Payne, and Stalein (1986) suggest that advertisers need to present product information
in a way to reduce consumers’ cognitive effort/time required to locate and retrieve information.
As a proxy measure of objective attention, perceived attention represents one type of indicator
for cognitive fluency and examining this construct may provide insight into through what
mechanism the effects of DTCA regulatory knowledge, risk disclosure prominence, and their
interplay on consumer information retrievability operates.
In general, higher attention is expected to lead to greater memory of information
(Goodrich, 2011). This is because more intensively attended and encoded information is more
likely to be retrieved from memory (Pieters, Warlop, & Wedel, 2002). In this regard, some
researchers view that enhanced information readability in terms of design can improve memory
performance of the ad and brand (Moore, Stammerjohan, & Coulter, 2005). Therefore, attention
to elements in advertising has been suggested as an important mediator of subsequent advertising
effectiveness outcomes, including recall, attitudes, and purchase intentions (Mackenzie, 1986)
and knowledge obtained from the ad (Chaffee & Schleuder, 1986).
Extending this perspective to the context of DTCA regulatory knowledge, enhanced
perceived attention resulting from higher DTCA regulatory knowledge and prominent risk
disclosure may also strengthen subsequent memory performance of risk information, and further
the interactive effects between DTCA regulatory knowledge and risk disclosure prominence will
be mediated through perceived attention on memory. In particular, given the moderating role of
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DTCA regulatory knowledge on the prominence effects, it is speculated that the mediating role
of perceived attention will be substantial for the prominence effects among low DTCA
regulatory knowledge consumers, whereas the mediating effects of perceived attention for the
prominence effects will be diluted among high DTCA regulatory knowledge consumers,
indicating a moderated-mediation relationship.
Based on the foregoing discussion, perceived attention may mediate the effects of DTCA
regulatory knowledge, risk disclosure prominence, and their interactive effects on consumers’
memory performance such as recall and recognition (Bettman et al., 1986; Sheehan, 2007).
Therefore, the following hypotheses can be raised:
H8: Perceived attention to risk disclosure will positively mediate the effects of risk
disclosure prominence on consumer (a) recall and (b) recognition of health risk
information.
H9: Perceived attention to risk disclosure will positively mediate the effects of
DTCA regulatory knowledge on consumer (a) recall and (b) recognition of
health risk information.
H10: Perceived attention to risk disclosure will positively mediate the interactive
effects of risk disclosure prominence and DTCA regulatory knowledge on
consumer (a) recall and (b) recognition of health risk information.

The research hypotheses of the current research are summarized in Table 1. In addition,
the conceptual framework of the research is illustrated in Figure 1.
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Table 1. Summary of Research Hypotheses
Risk Disclosure Prominence Main Effects:
H1: Higher risk disclosure prominence will lead to greater perceived attention to risk
disclosure.
H2: Higher risk disclosure prominence will lead to greater recall of health risk
information.
H3: Higher risk disclosure prominence will lead to greater recognition of health risk
information.
DTCA Regulatory Knowledge Main Effects:
H4: Higher DTCA regulatory knowledge will lead to greater perceived attention to risk
disclosure.
H5: Higher DTCA regulatory knowledge will lead to greater recall of health risk
information.
H6: Higher DTCA regulatory knowledge will lead to greater recognition of health risk
information.
Moderating Effects of DTCA Regulatory Knowledge:
H7: DTCA regulatory knowledge will negatively moderate the risk disclosure
prominence effects on consumer response to the ad; such that low DTCA
regulatory knowledge consumers will report higher (a) perceived attention to risk
disclosure, (b) recall, and (c) recognition for high prominence risk disclosure than
for low prominence risk disclosure, whereas high DTCA regulatory knowledge
consumers will show minimal prominence effects.
Mediating Effects of Perceived Attention:
H8: Perceived attention to risk disclosure will positively mediate the effects of risk
disclosure prominence on consumer (a) recall and (b) recognition of health risk
information.
H9: Perceived attention to risk disclosure will positively mediate the effects of DTCA
regulatory knowledge on consumer (a) recall and (b) recognition of health risk
information.
H10: Perceived attention to risk disclosure will positively mediate the interactive
effects of risk disclosure prominence and DTCA regulatory knowledge on
consumer (a) recall and (b) recognition of health risk information.
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CHAPTER 3: METHOD
Procedure and Sample
Prior to the data collection, pretests were undertaken to ensure subjects' understanding
and readability of the research instrument questions. In addition, the subjects in pretests served as
the function of manipulation check groups (Perdue & Summers, 1986; Wetzel, 1977) to examine
whether risk prominence was operationalized in a proper way. The test ads were reviewed by one
advertising professor and three other communication professors. Based on their
recommendations, the ad manipulations were revised several times to secure intended
operationalization of ad stimuli.
Then, confusing wording and unclear instructions were revised until the questionnaire is
became clear and easily understood. The main experiment manipulated the prominence of risk
disclosure by employing a set of message execution factors according to the FDA’s (2009) risk
communication guidance. To ensure less-biased research findings, random sample assignment
and statistical control of potential covariates were utilized according to the suggested
experimental research approach (Goodwin, 2008; Shadish, Cook, & Campbell, 2002). Further,
this approach has been also suggested in the health communication literature (e.g., An, 2007,
Park, Ju, & Kim, 2013; Ju & Park, 2013). Two different test ads were created for a fictitious
antidepressant brand (i.e., Luminexell) because mental depression is among major undertreated
social diseases (FDA, 2014) and a fictitious brand can exclude alternative explanations in
interpreting the findings (Shadish et al., 2002) (see the manipulation development section for
more information).
A US adult sample was obtained from a professional online consumer panel, Qualtrics. A
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set of factors recommended the use of online consumer panel to conduct this research. First, it
was an efficient way to reach relatively representative US adults. Second, the Internet access has
been grown rapidly and the generation gap has been continuously narrowed. Third, to enhance
the validity of the research, some of the questions were randomized to counterbalance any
potential order effects. In particular, regarding random sample assignment, the faster and easier
data collection allowed the researcher to better conduct research. Fourth, the Qualtrics consumer
panel software provides promising response validation check features, including attention filters
and average time duration screen out. There are many factors that may lead to respondent
fatigue. One way to reduce the number of “straight-liners” and “speeders” is to insert attention
filters into the survey. These questions verify respondents are reading the questions carefully and
are following instructions. The most common type of attention filters is asking respondents to
answer to “This is an attention filter. Please select “Strongly Disagree” for this statement.” If the
respondent did not follow the instruction, the response was excluded from the results.
In the same manner, to control the minimum time to submit the questionnaire, the
researcher can enforce 1/3 of the average survey duration found during the pilot test phase. If
there are respondents who attempt to take the survey in less than 1/3 the average time, the
responses were removed from the results. Furthermore, to ensure the measurement validity of
recall and recognition of risk disclosure, respondents were not allowed to go back to the previous
pages to see the ad again.
Regarding the online survey procedure, the online consumer panel members received an
e-mail announcement containing a brief description of the study with a link to the survey. The
first page of the survey showed consent form and asked if the respondents are at least 18 years
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old to participate according to the Institutional Research Board (IRB) protocol. The first page
ensured the purpose of the study broadly and assured anonymity.
By clicking the URL, the panel members directly logged on to the survey site. Subjects
who agreed proceeded to the survey. By the survey software, subjects were randomly assigned to
one of the manipulated treatment conditions. After answering some pre-measures including
DTCA regulatory knowledge measures, subjects were shown an antidepressant ad on the screen.
After viewing the ad, subjects completed manipulation check items and major dependent
measures. At the end of the survey, basic demographic information was asked.
More specifically, at the pre-measure stage, the instrument first measured potential
correlates (i.e., overall subjective health status, perceived importance of the disease, perceived
familiarity with the disease, and previous experience with the disease) and DTCA regulatory
knowledge.
Considering the artificial nature of the experiment, subjects were asked to read the ads
the same way as they would if they were at risk of mental depression in their real life. After the
subjects read the ad, they were asked to complete manipulation check items and dependent
measures. The survey duration mean was approximately 14 minutes to complete. The number of
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participants amounted to 264 1 that is a fairly sufficient sample size for the current research
design and the number of dependent variables.
A number of sources were considered to obtain a sample of adult consumers from diverse
demographic backgrounds. A convenience sample of 264 consumers were registered members of
the panel. The overall demographics consist of a random spread across the US. Though it was
not specifically mirroring the US census, the sample had a diverse representation. Specifically,
the sample represented diverse demographic background. Among the respondents (N = 264),
63.6% were males and 36.4% were females. The respondents ranged in age from 18 to 77 years
(M = 30.03, SD = 13.73). Among them, 43.9% were younger adults (18–44 years), 45.1% mature
adults (45–64 years), and 11% older adults (65 years or older). The majority were whites
(79.5%), followed by Black, not Hispanic (13.3%), Hispanic, of any race (4.5%), Asian or
Pacific Islander (1.1%), and American Indian, Eskimo, or Aleut (.8%).
In terms of respondent education, 27.7% of respondents attended some college education

1
The researcher originally collected the data from 420 individuals assigned to three conditions of disclosure
prominence. One of them was a condition designed for an exploratory purpose to be compared with the low
prominence condition. Since responses from the exploratory condition did not differ from the low prominence
condition, subjects in the former group were excluded from further analysis.
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without degree, followed by respondents completed high school but no college education
(25.0%), bachelor’s degree (17.8%), and associate’s degree (13.3%). The majority of
respondents had an annual household income of $25,000 to $99,999, with 62.1% reporting. In
addition, most respondents (87.9%) used laptop or desktop computers to participate in the
survey. The sample of this research is illustrated in Table 2.
It is worthy to note that 29.9% (n = 79) of the sample reported having been diagnosed
with clinical depression. Considering that an estimated 1 in 10 US adults reports current
depression (Center for Disease Control and Prevention, 2010), the current study’s sample may
over-represent the US adult population with depression experience. However, it is worth noting
that the survey instrument of the current study asks subjects to report their previous experience
with depression up to now. Given that the Center for Disease Control and Prevention (2010)
reports the current depression diagnosis (approximately 10%), it is possible to speculate that
subjects’ reported accumulative depression experience rate (approximately 30%) would be
higher than the current depression rate reported. That is, because subjects’ response in the current
research may represent not only current depression experience but also a whole personal history
of depression in their lifetime. Therefore, with careful caution, the higher depression experience
report of this research than that of the current epidemiological data seems to be understandable.

Design
Because the current study has one manipulated categorical variable with two levels (i.e.,
high vs. low prominence) and one measured continuous variable (i.e., DTCA regulatory
knowledge) along with control variables, a multiple regression approach was employed to probe
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the research hypotheses (Aiken & West, 1991; Fitzsimons, 2008). The current study did not
dichotomize the continuous DTCA regulatory knowledge levels (e.g., 0-6) into two categories
such as high and low. Fitzsimons (2008) notes that median-splitting of a continuous independent
variable has principal problems. First, dichotomizing continuous independent variables are likely
to unnecessarily reduce the statistical power available to test research hypotheses (Irwin &
McClelland, 2003). Second, a more serious potential problem is that inappropriate
dichotomization of continuous variables can create spurious significant results if the independent
variables are strongly correlated (Maxwell & Delaney, 1993). Third, inappropriate dichotomy of
the data is likely to loss important information by disregarding meaningful differences among
varying continuous levels (Fitzsimons, 2008). In this regard, Fitzsimons (2008) suggests to
follow a guide to performing analysis including continuous independent variables and
interactions proposed by Aiken and West (1991).
More specifically, when there are one straightforward manipulation of independent
variable and one measured continuous variable that is not easy to manipulate at the individual
consumer level or not appropriate for manipulating due to its nature such as pre-existing
cognitive traits, the researcher needs to decide whether he/she uses a continuous measure as it is,
to capture varying levels of the measured variable (Fitzsimons, 2008). However, more often than
not, when the researcher is interested in testing the interaction between the two independent
variables, a common mistake committed by the researcher is dichotomizing the measured
variable into two levels using a median-split method. However, this approach may be
inappropriate and possibly result in misleading interpretations of the results (Fitzsimons, 2008).
To address these limitations, Aiken and West (1991) suggest to perform regression
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analyses to utilize the continuous nature of the measured independent variable. Further, when the
researcher analyzes the interaction between one manipulated categorical variable and one
measured continuous variable, the Johnson-Neyman regions of significance procedure is
suggested as well as a simple slop analysis (Aiken & West, 1991; Preacher, Rucker, & Hayes,
2007). For instance, the Johnson-Neyman procedure shows where the subgroups’ (e.g. high vs.
low) regression slopes and intercepts are significantly different from one another across varying
levels of the measured variable. The regression slopes and intercepts can be plotted in graph and
the statistics of the method indicate the regions of significance. To further pinpoint the
interaction pattern, the simple slope analysis allows the researcher to examine the slopes of the
manipulated variable at each level of the measured variable. In the current research context, for
instance, the simple slope analysis shows whether the regression slopes are significantly different
between the two different manipulation conditions, at one standard deviation below the mean of
the measured variable, at the mean of the measured variable, and at one standard deviation above
the mean of the measured variable, (Aiken & West, 1991).
When the researcher addresses moderated mediation hypotheses, the use of the simple
slopes method and Johnson-Neyman technique are suggested as a rigorous and appropriate
analysis approach (Preacher et al., 2007). Further, to examine the mediating hypotheses,
asymptotic (i.e., interpreting confidence intervals) and resampling (e.g., 5,000 resamples)
strategies for assessing and comparing indirect effects, referred to as the bootstrap approach, are
suggested as a rigorous contemporary analysis (Preacher & Hayes, 2008). Taken together, given
the aforementioned methodological considerations and suggestions by methodologists, the
researcher judged that the use of multiple regressions, along with Johnson-Neyman procedure,
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the simple slopes method, and the bootstrap approach are appropriate for probing the research
hypotheses of the current research.

Table 2. The Sample Profile of Study Respondents (N = 264)
N

%

168
96

63.6%
36.4%

119
116
29

45.1%
43.9%
11%

210
35
12
3
2

79.5%
13.3%
4.5%
1.1%
.8%

73
66
47
35
21
8
6
7
1

27.7%
25.0%
17.8%
13.3%
8.0%
3.0%
2.7%
2.3%
.4%

75
73
66
23
18
9

28.4%
27.7%
25.0%
8.7%
6.8%
3.4%

Gender
Male
Female
Age
45-64
18-44
65 and older
Ethnic Background
White, not Hispanic
Black, not Hispanic
Hispanic, of any race
Asian or Pacific Islander
American Indian, Eskimo, or Aleut
Education
Some college education but no degree
Completed high school but no college education
Bachelor’s degree (examples: BA, BS)
Associate's degree (examples: AA, AS)
Master's degree (examples: MA, MBA)
Attended graduate school but no degree
Did not finish high school
Doctorate degree (examples: PhD, EdD)
Professional degree (examples: JD, MD)
Annual Household Income
$25,000 ~ $49,999
Lower than $25,000
$50,000 ~ $74,999
$75,000 ~ $99,999
$100,000 ~ $149,999
$150,000 or higher
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Manipulation of Independent Variable: Prominence
Pretests and Manipulation Checks
Antidepressant ads for a fictitious brand were generated to exclude potential biases from
prior experience or perception regarding the brand. The current study focuses on mental
depression because it represents one prevalent but undertreated health issue among US adults
(Gonzales, Tarraf, Whitfield, & Vega, 2010; Kessler et al., 2003; Rosenthal, Berndt, Donohue,
Frank, & Epstein, 2002). The Centers for Disease Control and Prevention (2014) indicates that
each year approximately 10% of US adults aged ≥ 12 years reported current depression during a
period of 2007-2010. Examining consumers’ response to an antidepressant DTC ad will
illuminate DTCA’s potential contribution to consumer education and public health.
More specifically, a number of factors were considered to select the antidepressant
DTCA category among various therapeutic categories. First, among the top 20 most advertised
prescription drugs, mental depression is one of highly stigmatized conditions (An & Kang, 2011;
Donohue, Cevasco, Rosenthal, 2007; Park & Grow, 2008). In this regard, understanding the
educational value of antidepressant DTCA may provide insight into reducing social stigma
associated with the disease category (An & Kang 2011). Second, mental depression is the most
common form of mood disorders that deserve research attention (Park & Grow, 2008). Third,
mental depression remains as a largely under-diagnosed and under-treated illness category
(Holmer, 2002), which calls for consumer education to promote disease diagnosis and treatment.
DTCA has been considered one potential health education source (Royne & Myers, 2008).
Although approximately 10% of US adults reported their current depression during 2007-2010,
recent national data suggest that only 8.7% of Americans have used an antidepressant in the past
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month during the same period (National Center for Health Statistics, 2013; Health, United States,
2012). More specifically, in terms of gender, 5.3% of male respondents reported that they have
used antidepressants, while 11.9% have used antidepressants in past 30 days (CDC, National
Center for Health Statistics. Health, United States, 2012). This suggests that male consumers still
need appropriate medical treatments along with other life style remedies. Fourth, antidepressant
DTCA is targeted at a potentially vulnerable consumers with symptoms such as feeling of social
isolation and worthlessness (Park & Grow, 2008). Addressing this category has important social
implications. Fifth, antidepressant treatments contribute to reduced risk of suicide (Olfson,
Shaffer, Marcus, & Greenberg, 2003) and lower suicide rates (Gibbons, Hur, Bhaumik, & Mann,
2006). Sixth, depressive disorders often harm social, occupational, and role functions and
thereby have detrimental consequences on quality of life (Olfson et al., 2002). Olfson et al.,
(2002) notes that the negative effects of depression on daily function of individuals match that of
heart disease, and exceed that of diabetes, arthritis, and peptic ulcer disease. Seventh, according
to the Global Burden of Disease Study (Murray & Lopez, 1996), major depression is the fourth
leading cause of worldwide disability and is speculated to become the second leading cause by
2020. Eighth, among persons diagnosed with and receiving treatment for depression, the second
highly used treatment method was antidepressant (75.3%) followed by physician visits (84.6%)
(Marcus & Olfson, 2010). Considering that antidepressant DTCA spending is positively
associated with antidepressant uses (Donohue & Burndt, 2004), addressing consumer response to
antidepressant DTC ads will add invaluable insights into promoting depression diagnosis and the
treatment-expanding role of DTCA (Park & Grow, 2008).
Given the importance of antidepressant DTCA, the prominence of risk disclosure was
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manipulated through combining various message execution factors simultaneously based on the
FDA’s (2009) draft guidance for pharmaceutical marketers’ risk communication. To be more
specific, high risk disclosure prominence was operationalized as a combination of using box
outlines (vs. running text without box lines), a larger font size (14 vs. 10), red colored texts (vs.
black), bold type (vs. regular), bulleted texts (vs. no bullets), and proximate placement to use
information. In contrast, to operationalize the low prominence condition, the above message
devices were employed in opposite ways (see appendix B & C). As a result, except major health
risks of the drug (i.e., manipulation), all other design elements were equivalent across different
experimental conditions. Graphics were exactly the same and word counts were largely
equivalent across the two conditions (i.e., 221 for low prominence; 227 for high prominence).
To secure proper manipulation, two pretests were conducted. In the first pretest, 58
college students from a northern state university participated. In the second pretest, 59 college
students from different state universities participated. To check whether risk disclosure
prominence was successfully manipulated, subjects were asked to indicate on a 7-point scale (1 =
not at all prominent, 7 = extremely prominent) their agreement with “How prominent do you feel
was the information in the ad about the health risks of Luminexell?”
In the first pretest, the manipulation check results and respondents’ solicited focus group
interview were analyzed (Griffin, Babin, & Darden, 1992). The customized simple method
contrast test results for the first pretest indicated that the manipulation of risk disclosure
prominence was not successful, Mlow-prominence = 3.61, SD = 1.41, Mhigh-prominence = 3.81, SD = 1.47,
difference value (estimate – hypothesized) = -.31, SE = .38, p > .05. The results were discussed
with an experienced advertising professor to modify the manipulation to be more appropriate,
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and then the researcher determined to conduct the second pretest after revising the stimuli and
manipulation check items.
In the second pretest phase, two ad stimuli were generated by using professional visual
design softwares, including Adobe Creative Cloud Indesign and Photoshop. Subjects were
shown the ads and reported their impression about prominence of risk disclosure in the ads. A
simple method planned contrast test was performed, using the statement “How prominent do you
feel was the information in the ad about the health risks of Luminexell?” with endpoints of “not
at all prominent” and “extremely prominent.” The results showed that the manipulation of risk
disclosure prominence was successful, (Mlow-prominence = 3.27, SD = 1.49, Mhigh-prominence = 4.21, SD
= 1.75, difference value (estimate – hypothesized) = -.94, SE = .44, p < .05.
Based on the pretest results, in the main test the manipulation check was also conducted,
in order to confirm the test ads were operationalized as the researcher intended. The GLM
univariate test results showed that the manipulation of risk disclosure prominence was
successful, Mlow-prominence = 4.41, SD = 1.60, Mhigh-prominence = 5.03, SD = 1.52, F(1, 262) = 10.43,
p ≤ .001. The customized contrast test using the simple method confirmed that the manipulation
was successful as the researcher intended, with the difference value (estimate – hypothesized) = .62, SE = .19, p ≤ .001. Taken together, these results clearly indicate the success of manipulation
in that the comparisons between high and low prominence conditions revealed statistically
significant perceptual difference regarding risk disclosure prominence.
It is worth noting that the procedure of conducting the instrument of this study, including
the positioning of each measure of constructs in the questionnaire, was carefully designed based
on the consumer research and marketing literature (e.g., Aronson & Carlsmith, 1968; Keppel.,
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1982; Keppel & Wickens, 2004; Purdue & Summers, 1986; Shadish, Cook, & Campbell, 2002).
First, random assignment of subjects to study treatment conditions facilitates causal
interpretation by excluding potential systematic extraneous factors (Keppel & Wickens, 2004;
Shadish et al., 2002). In particular, manipulation and confounding checks appear to have critical
value during the pretest/pilot test, because the cost associated with negative results at this phase
is relatively small, whereas the cost associated with unfavorable results is high in the main
experimental stage (Perdue & Summers, 1986).
Among others, the timing of manipulation and confounding checks is worthy to note (i.e.,
before or after dependent measures). In general, extensive testing of the manipulations in the
pretest phase could lessen the need for manipulation and confounding checks in the main
experiment if this testing is conducted with the same procedures, experimental instruments, and
subject types as the main experiment (Purdue & Summers, 1986). In this regard, the current
research employed almost the same procedure, experimental instruments, and subject types to
reduce variations between the pretests and main experiment. Further, the current research
followed a widely suggested experimental procedure that runs the major experiment only after
the manipulation checks are found to be successful in the pre-test phase. Nevertheless, to secure
the success of manipulation in the main test, manipulation and confounding checks were also
included in the main experiment (Kerlinger & Lee, 2000; Shadish et al., 2002).
The reason of including such checks before dependent measures in the main experiment
was because the researcher judged that ensuring appropriate operationalization of the
independent variable (i.e., prominence) is critical given the FDA’s concern about risk disclosure
prominence. Further, potential correlates of criterion variables identified and adopted from the
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health communication literature were measured before stimuli, because those constructs are
individuals’ pre-existing cognitive traits that need to be treated as persistent characteristics rather
than immediate responses to the experimental stimuli. Therefore, according to the consumer
experimental convention in the literature, the current research performed the measurement of
potential correlates before subjects were shown experimental test ads.
In addition, the inclusion of manipulation and confounding checks before dependent
measures can be justified based on the literature on experimental methodology. Specifically,
research suggests that subjects should be interviewed to complete manipulation and confounding
checks immediately after exposure to the manipulation (Aronson & Carlsmith, 1968; Purdue &
Summers, 1986). Waiting until after the dependent variables have been assessed is likely to
decrease the subject’s capacity to fully indicate their responses to the manipulation and could
bias their reports (Purdue & Summers, 1986). Moreover, the researcher conducted solicited
interviews with pretest participants as supplemental qualitative techniques (Aronson &
Carlsmith, 1968). These methods can offer a better perspective of how the desired variance in the
intended independent variable can be operated (Purdue & Summers, 1986).
With regard to manipulation checks in the main experiment, although some suggest that
dependent measures should be conducted first due to demand characteristics associated with selfreports or other forms of obtrusive measurement (Wetzel, 1977), measuring the dependent
variables before conducting the manipulation assessment presents a set of potential problems.
First, when the manipulation checks come after the dependent measures, important effects of the
manipulation could already have dissipated because the manipulation effects would be temporary
in the level of the independent or any confounding variable (Purdue & Summers, 1986). In
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particular, when these checks involve self-report measures, subjects’ responses to the dependent
measures could bias their reactions to the subsequent manipulation checks (Kidd, 1976).
In this study, the manipulation check results appeared to be significant, Mlow-prominence =
4.41, SD = 1.60, Mhigh-prominence = 5.03, SD = 1.51, F(1, 262) = 10.43, p ≤ .001, whereas the
confounding check did not show significant results, Mlow-prominence = 5.16, SD = 1.17, Mhighprominence

= 4.98, SD = 1.45, F(1, 262) = 11.26, p > .10, using the statement “How prominent do

you feel was the information in the ad about the uses of Luminexell?” with endpoints of “not at
all prominent” and “extremely prominent.” Although use of confounding checks has been rarely
employed in marketing experiments despite its importance (Purdue & Summers, 1986), the
current research utilized the confounding check and further demonstrated that the manipulation
was successful with less concern about potential confounding.
To address alternative insights for the ordering of manipulation checks and dependent
measures, Kidd (1976) suggests the creation of manipulation check groups whose sole purpose is
the assessment of manipulation success. However, Wetzel (1977) argues that the subjects in a
pretest serve the function of Kidd’s (1976) manipulation check groups. In this study, a series of
pretests ensuring the equivalence between the pretests and the main experiment clearly support
the manipulation of prominence was successful, and the pattern of prominence effects on major
dependent variables were similar, indicating that the potential problem of the ordering effects of
manipulation checks before dependent variables are less plausible.
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Measurements
Measured Independent Variable: DTCA Regulatory Knowledge
DTCA regulatory knowledge was measured using multiple items adopted from the
FDA’s consumer education webpage regarding prescription drug advertising, For Consumers &
Patients (FDA, 2014). The FDA provides health information on its website for consumers to stay
safe and healthy. On the website, consumers can obtain information by topic such as cosmetics,
drugs, food, medical devices, and tobacco products. If consumers click on the drugs menu, they
are linked to various information sources regarding the use of drug such as educational
resources, buying & using medicine safely, tips for seniors, tips for parents, and prescription
drug advertising.
Consumers can navigate detailed information through clicking on the prescription drug
advertising menu from the left side navigation column. The linked page shows important and
relevant information regarding prescription drug advertising, including the background of drug
advertising, basics of drug ads, questions to ask yourself, and sample prescription drug
advertisements, in order to promote general knowledge of the DTCA category. Among others,
the page provides consumers with frequent questions and answers (Q&A) regarding prescription
drug advertising to inform consumers about the DTCA category’s regulatory context. The
current research borrows the DTCA knowledge measure items from the Q&A section, because it
best represents the current FDA’s thought and consumers’ most frequent questions regarding the
DTCA category.
Individuals’ DTCA regulatory knowledge has been neither measured nor controlled in
the literature. Therefore, developing the measurement of this construct was critical for this
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research. The measurement of knowledge has long been a subject in the marketing literature
(e.g., House et al., 2004; Park et al., 1994). The current research adopted a widely suggested
approach to measure DTCA regulatory knowledge. The objective measure of DTCA regulatory
knowledge was designed as series of six true/false items. According to previous research
approach (Park et al., 1994), the items were selected from the FDA’s consumer education page
through discussions with DTCA experts and from modifications of the pretest items.
More specifically, to establish the validity of the measurement, the items were reviewed
by professional DTCA researchers, and selected and refined to form a better measurement scale
for the intended construct. The measure items included: (1) The FDA bans consumer-directed
ads for prescription drugs that have serious health risks; (2) The FDA requires drug companies to
use hard-to-understand medial language in prescription drug ads directed to consumers; (3) The
FDA works with drug companies to create prescription drug ads directed to consumers; (4) The
FDA approves prescription drug ads before they are seen by the public; (5) The FDA regulates
the design of prescription drug ads directed to consumers; and (6) The FDA conducts research to
examine consumer attitudes and behaviors toward prescription drug advertising (see Table 3 &
4). The mean for DTCA regulatory knowledge was 2.09 (SD = 1.29), indicating an overall low
knowledge level. A one sample t-test results shows that the average DTCA regulatory knowledge
is significantly lower than the mid-point (3.5), t(263) = -17.79, p < .001.
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Table 3. Percentage of Right Answers for DTCA Regulatory Knowledge
Items

Percentage of
Right Answers

The FDA
bans
consumerdirected ads
for
prescription
drugs that
have serious
health risks

The FDA
requires drug
companies to
use hard-tounderstand
medial
language in
prescription
drug ads
directed to
consumers

The FDA
works with
drug
companies to
create
prescription
drug ads
directed to
consumers

The FDA
approves
prescription
drug ads
before they
are seen by
the public

The FDA
regulates the
design of
prescription
drug ads
directed to
consumers

The FDA
conducts
research to
examine
consumer
attitudes and
behaviors
toward
prescription
drug
advertising

38.6%

62.1%

27.7%

20.8%

29.5%

30.3%

Table 4. Descriptives for DTCA Regulatory Knowledge
Number of Right Answers
0
1
2
3
4
5
6
Total

N
34
47
96
41
40
6
0
264

%
12.9
17.8
36.4
15.5
15.2
2.3
0
100

Dependent Variable: Perceived Attention to Risk Disclosure
The measurement of attention poses a major challenge to consumer researchers. Three
general approaches are found to have been employed in the consumer psychology literature:
inferences based on observed behaviors, psycho-physiological techniques, and self-reports
(Chaffee & Schleuder, 1986). To provide a foundation for the use of perceived attention to risk
disclosure in this research, in this section prior research is reviewed with the justification of the
measurement approach of current research.
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First, the behavioral observation approach has assessed the movements of people who
were filmed while watching stimuli by carefully coding facial expressions (Ekman et al., 1972),
by observing participants’ eye gaze or aversion during experimental presentations of messages
(Alwitt, Anderson, Lorch, & Levin, 1980), and by measuring reaction times to a message
(Meadowcroft & Reeves, 1985).
Second, in terms of the psycho-physiological measurement, experimental psychology and
psychophysiology have examined blood pressure, galvanic skin response (Zillmann, 1982) and
brain wave activity (Thorson, Reeves, & Schleuder, 1985). In particular, eye-tracking
methodology has been one of the most popular approaches to measure attention. Because
attention to advertisements cannot be directly inferred from consumers’ memory, it is useful to
examine consumers’ actual eye (e.g., pupil) movements. Specifically, cameras track the eye and
head position, and allow for continuous correction of position shifts. A couple of indicators of
visual attention can be assessed including ad (i.e., entire ad page) gaze duration and ad-element
gaze duration (Krugman et al., 1994; Pieters, 2008). Ad gaze duration is the total time that
consumers who selected the ad, on average, spent on it, and measures how well an ad retains
consumers in its environment. Ad-element gaze duration assesses the time spent on each of the
ad elements (Pieters & Wedel, 2004). Eye-tracking methodologies may be promising because
gaze can be used as a proxy measure for a consumer’s attention (Cutrell & Guan, 2007). While
many measurement approaches of attention rely on the explicit actions of consumers such as
mouse clicks, query streams or diary reports, eye tracking can provide more detailed moment-bymoment observations about how consumers interact with messages (Cutrell & Guan, 2007).
Third, with regard to self-reports, a consumer is asked to recall prior mental states
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regarding attention perception. This methodological approach is employed not because it is an
ideal method, but because for many research purposes it is the only measure available (Chaffee
& Schleuder, 1986). In experimental effects research, correlations between objective attention
and self-reported attention measures have been employed as a validity check (e.g., Krull &
Husson, 1979; Reeves et al., 1985) and introspective self-observation is commonly utilized in
survey research (Chaffee & Schleuder, 1986).
The above three general approaches to attention measurement have their own advantages
and disadvantages. Although behavioral observation provides an indicator for natural attention
setting, one cannot assume that its effects can be tested in the same way as with more closely
attended messages. Although psychophysiological approaches offer more reliable and accurate
measures for attention, more often than not, the resources and instruments are not available for
researchers. Further, these approaches have limitations in providing an immediate solution to
multivariate filed research where attention to various media is to be measured. (see Chaffee &
Schleuder, 1986 for more information).
Given the foregoing review of literature on attention measurement, there are various
ways to conceptualize and measure attention to messages. However, all these approaches are
viewed as legitimate and valuable and methodologically the simplest way to operationalize
attention is self-reports (Reeves & Thorson, 1986; Thorson et al., 1992). For this reason and
given limited resources, the self-reported intensity of attention (i.e., perceived attention) is
employed in the current research.
To assess the extent of subjects' perceived attention to risk disclosure prominence, a
single-item 7-point Likert-type scale was adopted from prior research (Thorson et al., 1992) and
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modified for the current study context: “How much attention did you pay to the information
about the health risks of Luminexell?” (1 = no attention, 7 = great attention). The mean for
perceived attention was 5.78 (SD = 1.29) (see Table 5). Overall, subjects reported relatively high
perceived attention. 39% (n = 103) of the sample reported “great attention.” This high number
raises caution in interpreting the results. For instance, due to the artificial nature of experiment or
obtrusive self-reported measure, the overall attention score could have been inflated. The overall
frequency distribution of perceived attention was negatively skewed (skewness = -.84, SE = .15),
indicating lack of symmetry. In addition, subjects’ reported average attention score was higher
than the midpoint (4), using a one-sample t-test, t(263) = 22.42, p < .001.
Dependent Variables: Recall and Recognition
Advertising research has employed recall and recognition as important effectiveness
measures (Moore, Stammerjohan, & Coulter, 2005). In particular, considering that the major
purpose of risk disclosure is to encourage consumers to utilize provided risk information in their
decision making (Andres et al., 2009; Burton, Andrews, & Netemeyer, 2000), examining recall
and recognition of risk information in DTCA may provide meaningful insight into consumer
health education. In addition, research on advertising attention has measured recall and
recognition as major criterion variables (Rosbergen et al., 1997).
In general, the most widely employed two memory measures in advertising research are
unaided-recall that is an open-ended question, and aided-recognition measure that provides a list
of choices to allow respondents to indicate whether each choice was presented in the ad
(Rosbergen et al., 1997). In this research, the recall test was an open-ended question asking
subjects to write all health risks that were presented in the ad as much as they can recall. The
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recall test statement read “The ad presented the health risks of Luminexell. In the box below,
please write all the health risks of Luminexell you can recall from the ad. (Lynch & Srull, 1982)”
To appraise recognition, subjects were provided with a checklist that presents a list of ten health
risks. Five of which were the health risks of the drug presented in the ad, and the remaining five
of which were "distracter" (false) health risks that were not presented in the ad (Davis, 2010;
Lynch & Srull, 1982). The order of health risks were randomized using the Qualtrics software
feature. The number of explicitly right answers for the recall test was coded by the researcher. In
the same vein, the number of right answers for the recognition test was coded. For both
measures, one right answer counted one point and the points were summed to form a composite
score for each memory construct.

Table 5. Descriptives for Perceived Attention
Attention Levels
1
2
3
4
5
6
7
Total

N
0
4
9
41
37
70
103
264

%
0
1.5
3.4
15.5
14.0
26.5
39.0
100

It is worth noting that the current research especially uses a recognition task to assess
explicit memory retrieval because recall performance is generally reported as low (Shapiro &
Krishnan, 2001). To maximize the measurement validity, two methods were utilized. First, ten
health risks were randomly shown to counterbalance potential order effects. Second, the
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researcher considered whether the subject accurately or randomly chose the answer. To do so,
when the subject indicated “yes” for the presented health risk, the researcher gave one point.
Furthermore, to prevent inaccurate and biased random choice, when the subject indicated “no”
for the health risk that was not presented (i.e., distractor), the subject was also given one point.
However, when subjects failed to accurately recognize whether a particular health risk was
shown in the ad, they did not obtain points. When the subject chose “don’t know” or a wrong
answer, the answer was given 0. As a result, when the subject correctly answered for all choices,
his/her score could add up to 10, whereas when the subject’s all answers were wrong or
ambiguous (i.e., don’t know), the score could be 0. The summed single composite score for
recognition measure was reliable (Cronbach’s α = .79). The mean for the recognition score was
5.64 (SD = 2.88), indicating an overall high performance. 5.3% (n = 14) scored 0, whereas
10.2% (n = 27) scored 10 (see Table 6).
On the other hand, the recall score was coded by the researcher. When the subject
reported explicitly correct health risk names that were presented in the ad, each correct answer
was given one point. Therefore, when the subject correctly answered for all the five health risks
presented in the ad, his/her score could add up to 5, whereas when he/she provided no right
answers at all, his/her score could be 0. The mean for the recall score was 1.07 (SD = 1.16),
indicating an overall low retrieval performance. Approximately 40% (n = 105) of the sample
scored 0 (see Table 7). Whereas the recognition score was appropriate for calculating
measurement reliability (internal consistency), the recall score was not appropriate for
calculating a coefficient value. Further, given that only explicitly correct answers were coded as
right answers, it was not necessary to conduct an inter-coder reliability test for the recall test.
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Table 6. Descriptives for Recognition
Number of Right Answers
0
1
2
3
4
5
6
7
8
9
10
Total

N
14
6
19
34
21
36
28
20
30
29
27
264

%
5.3
2.3
7.2
12.9
8.0
13.6
10.6
7.6
11.4
11.0
10.2
100

N
105
73
53
28
3
2
264

%
39.8
27.7
20.1
10.6
1.1
.8
100

Table 7. Descrptives for Recall
Number of Right Answers
0
1
2
3
4
5
Total

Covariates
Several potential covariates of consumer response to DTCA were identified from the
DTCA literature and measured to be controlled and to exclude alternative explanations of the
findings. According to DTCA research and the health communication literature in general, various
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pre-existing cognitive traits could affect consumer response to DTCA (e.g., An, Jin, & Brown,
2009, Park et al., 2013; Ju & Park, 2013), including current health status, subjective familiarity
and perceived importance of a disease, and personal experience with a disease. Such cognitive
variables are known to increase or decrease personal involvement with health product advertising
information (An et al., 2009; Park et al., 2013). Therefore, the current research attempted to
account for the influences of such variables. Specifically, subjects indicated on a four-point scale
(1 = poor, 2 = fair, 3 = good, and 4 = excellent) how they rated their overall health at the present
time (M = 2.69, SD = .74) (An et al., 2009; Park et al., 2013; Ju & Park, 2013). Perceived familiarity
with depression was measured on a seven-point scale (1 = not at all familiar, 7 = very familiar; M
= 4.62, SD = 1.72) (Ju & Park, 2013). According to a DeLorme, Huh, and Reid’s (2009) analytical
approach, to test whether or not this mean score was significantly different from the mid-point, a
one sample t-test was conducted with the mid-point (4) as a test value. The results indicated
significant difference (t = 5.83, df = 263, p < .001). Perceived importance given to depression was
assessed on a seven-point scale (1 = not at all important, 7 = very important; M = 4.81, SD = 1.78)
(Laffrey & Isenberg, 1983; Ju & Park, 2013). To test whether or not this mean score was
significantly different from the median point, a one sample t-test was conducted with the mid-point
(4) as a test value. The results indicated significant difference (t = 7.43, df = 263, p < .001). Prior
experience with depression was measured using yes/no response options (An et al., 2009; Park &
Grow, 2008; Park et al., 2013; Ju & Park, 2013). About 30% of subjects reported having been
diagnosed with depression. These potential covariates were submitted to regression analyses for
their potential influence on dependent variables to be controlled (Hair, Anderson, Tathan, & Black,
1998). In addition, to ensure how much subjects are knowledgeable about mental depression in
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general, their subjective (perceived) knowledge about clinical depression was measured (M = 4.32,
SD = 1.67). A one sample t-test was conducted with the mid-point (4) as a test value. The results
indicated significant difference (t = 3.13, df = 263, p < .01). The results from a series of t-tests
imply that subjects of the current research have a reasonably good understanding of what clinical
depression is (see Appendix A for more information regarding measure items).
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CHAPTER 4: ANALYSIS AND RESULTS
Analysis Approach
To analyze the data, descriptive and inferential statistics were utilized. In terms of
descriptive statistics, correlations among the major study variables are summarized along with
means and standard deviations in Table 8. To test the main and interaction effect hypotheses, the
current research employs a series of multiple regressions. In particular, because DTCA
regulatory knowledge was measured using a quantitative composite score, regression analysis
helps the researcher prevent from unnecessary loss of information and statistical power due to
dichotomizing the knowledge level into a few categorical groups (Fitzsimons, 2008). In addition,
to further pinpoint the patterns of interaction between DTCA regulatory knowledge and
prominence on dependent variables, regression slopes and intercepts for each subgroup (high
prominence vs. low prominence) were interpreted. Specifically, the Johnson-Neyman’s
significance region procedure and simple slop analysis were performed to see where the
significant prominence effects exist among varying levels of DTCA knowledge. As to the
mediation tests, this research employs the bootstrap approach because the method is suggested as
a superior approach to the traditional Baron and Kenny method (Preacher & Hayes, 2004, 2008;
Zhao, Lynch Jr., & Chen, 2010).
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Table 8. Inter-Correlations among Major Variables of Study
Major Variables
1. Prominence
2. DTCA Knowledge
3. Perceived Attention
4. Recall
5. Recognition
Note: ** Significant at .01

Prominence
1
-.006
.186**
.167**
.220**

DTCA
Knowledge

Perceived
Attention

1
.207**
.027
.083

1
.267**
.379**

Recall

Recognition

1
.437**

1

The Results of Hypothesis Tests
Hypotheses 1 through 6: Prominence and DTCA Knowledge Main Effects
To examine the hypotheses 1-6, moderated hierarchical analyses were used. As a check
for multicollinearity, the researcher calculated variance inflation factor (VIF) scores for all
variables in each regression model. As shown in Table 9, 10, and 11, all VIF scores were less
than 2, suggesting that muticollinearity was not a serious problem in the analysis (Oke,
Walumbwa, & Meyers, 2012). To control potential correlates, gender, age, education, and
household income were entered as general demographic control variables at Step 1. Then, the
correlates of consumer response to the DTC ad identified in the literature were submitted at Step
2, including overall health status, perceived familiarity, perceived importance, and prior
experience. At Step 3, prominence and DTCA regulatory knowledge were entered. Finally, the
prominence × DTCA regulatory knowledge interaction was entered at Step 4. List-wise deletions
accounted for missing values.
Table 9 summarizes the results of the regression on the extent of perceived attention. The
results showed that risk disclosure prominence had significant effects on perceived attention (b =
.589, SE = .186, p < .01, supporting H1. In addition, DTCA regulatory knowledge had significant
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effects on perceived attention (b = .281, SE = .072, p < .001), supporting H4.
The same procedure was used to examine the prominence main effects on recall. To
control potential correlates, gender, age, education, and household income were entered as
general demographic control variables at Step 1. Then, the correlates of consumer response to the
DTC ad identified in the literature were submitted at Step 2, including overall health status,
perceived familiarity, perceived importance, prior experience. At Step 3, prominence and DTCA
regulatory knowledge were entered. Finally, the prominence × DTCA regulatory knowledge
interaction was entered at Step 4. List-wise deletions accounted for missing values.

Table 9. Moderated Hierarchical Regression on Perceived Attention (N = 264)
Predictors

b (SE)

Step 1
Gender
Age
Education
Annual household income

-.021 (.165)
.004 (.006)
-.054 (.048)
.064 (.065)

Overall health
Perceived familiarity
Perceived importance
Personal experience

.020 (.110)
.087 (.063)
.116 (.059)
-.071 (.196)

Risk disclosure prominence
DTCA regulatory knowledge

.589 (.186)**
.281(.072)***

Prominence × DTCA knowledge

-.606 (.274)*

Step 2

Block ∆R2

Statistics
Block ∆F

.007

.450
1.14
1.12
1.28
1.36

.076

Step 3

5.308***
1.18
2.09
2.01
1.45

.053

Step 4

Variance Inflation Factor
(VIF)

7.833**
1.56
1.56

.016

4.896*
1.91

Note. Adjusted R2 = .116, *p < .05, **p < .01, ***p < .001

Table 10 summarizes the results of the regression on the extent of risk information recall.
The results showed that risk disclosure prominence did not have significant effects on risk
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disclosure recall (b = .161, SE = .166, p > .05. The results did not support H2. In the same vein,
DTCA knowledge did not have significant effects on risk disclosure recall (b = -.011, SE = .064,
p > .05). H5 was not supported.

Table 10. Moderated Hierarchical Regression on Recall (N = 264)
Predictors
Step 1
Gender
Age
Education
Annual household income
Step 2
Overall health
Perceived familiarity
Perceived importance
Personal experience
Step 3
Risk disclosure prominence
DTCA regulatory knowledge
Step 4
Prominence × DTCA knowledge

b (SE)

Block ∆R2

.064

Statistics

Block ∆F

4.463**

.241 (.147)
-.009 (.005)
.041 (.043)
.103 (.058)

1.14
1.12
1.28
136
.032

2.246

-.102 (.098)
.024 (.056)
.028 (.053)
.215 (.174)

1.18
2.09
2.01
1.15
.009

1.203

.161 (.166)
-.011(.064)

1.56
1.56
.002

.166 (.244)

Variance Inflation Factor (VIF)

.461
1.91

Note. Adjusted R2 = .067, **p < .01

The same procedure was used to examine the prominence main effects on recognition. To
control potential correlates, gender, age, education, and household income were entered as
general demographic control variables at Step 1. Then, the correlates of consumer response to the
DTC ad identified in the literature were submitted at Step 2, including overall health status,
perceived familiarity, perceived importance, prior experience. At Step 3, prominence and DTCA
regulatory knowledge were entered. Finally, the prominence × DTCA regulatory knowledge
interaction was entered at Step 4. List-wise deletions accounted for missing values.
Table 11 summarizes the results of the regression on the extent of risk information
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recognition. The results showed that risk disclosure prominence had significant effects on risk
disclosure recognition (b = 1.374, SE = .432, p < .01, supporting H3. In the same token, DTCA
regulatory knowledge had significant effects on risk disclosure recognition, supporting H6.

Table 11. Moderated Hierarchical Regression on Recognition (N = 264)
Predictors
Step 1
Gender
Age
Education
Annual household income
Step 2
Overall health
Perceived familiarity
Perceived importance
Personal experience
Step 3
Risk disclosure prominence
DTCA regualtory knowledge
Step 4
Prominence × DTCA knowledge

b (SE)

Block ∆R2

.011

Statistics
Block ∆F

.726

.089 (.384)
-.008 (.013)
-.006 (.111)
.047 (.151)

1.14
1.12
1.28
1.36
.033

2.206

-.326 (.256)
-.052 (.146)
.114 (.138)
.561 (.454)

1.18
2.09
2.01
1.15
.036

4.961**

1.374 (.432)**
.338 (.168)*

1.56
1.56
.008

-.951 (.636)

Variance Inflation Factor (VIF)

2.235
1.91

Note. Adjusted R2 = .067, **p < .01

Hypotheses 7a, 7b, and 7c: Moderating Effects of DTCA Regulatory Knowledge
As shown, in the previous sections, moderated hierarchical regressions on perceived
attention (see Table 4), recall (see Table 5) and recognition (see Table 6) were performed.
Among the three criterion variables, DTCA regulatory knowledge was found to positively
moderate the effects of risk disclosure prominence on perceived attention. The block including
the prominence × DTCA regulatory knowledge was associated with a significant increase in
explained variance in perceived attention (∆R2 = .016, p < .05), supporting H7a. However, the
interaction was not significant on recall and recognition and therefore H7b and H7c were not
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supported.
Specifically, according to Aiken and West (1991), to assess possible prominence
differences in both the intercept and slope for prediction of the extent of perceived attention, the
moderated hierarchical regression was performed to predict perceived attention from prominence
(dummy coded 1 = high, 0 = low), DTCA regulatory knowledge, and a product term to represent
a prominence-by-DTCA regulatory knowledge interaction. The overall regression was
statistically significant, and explained a fair proportion of the variance in perceived attention, R =
.391, adjusted R2 = .116, F (11, 252) = 4.143, p < .001. Further, the interaction between
prominence and DTCA knowledge was statistically significant, with b = -.606, t (252) = -2.213,
p < .05. The regression equations to predict perceived attention from DTCA regulatory
knowledge were as follows:
High prominence subgroup: 5.83 + .09 × DTCA Regulatory Knowledge
Low prominence subgroup: 4.85 + .33 × DTCA Regulatory Knowledge
These two regressions are graphed in Figure 2. High and low prominence risk disclosures
did not considerably differ among high DTCA regulatory knowledge consumers, whereas among
low DTCA regulatory knowledge consumers’ perceived attention was considerably higher in
response to high prominence risk disclosure. In addition, the predicted perceived attention
increase for low prominence (.33) was higher than the predicted perceived attention increase for
high prominence (.09). This shows that as knowledge increases, the difference in the level of
attention between low knowledge and high knowledge groups will decrease. The predicted
perceived attention increase per DTCA regulatory knowledge was 0.24 higher for low
prominence individuals than for high prominence individuals.
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A simple slopes analysis confirms this pattern. When knowledge was low (corresponding
to one standard deviation lower than the mean), and medium (corresponding to the mean), the
high prominence condition led to a higher level of attention (p < .05), whereas it did not when
knowledge was high (p > .05). Application of the Johnson-Neyman technique shows that the
difference between high and low prominence conditions would be significant when DTCA
knowledge was 2.50 or lower on the five-point scale. These patterns of slopes and intercepts
support the hypothesized main effects of prominence and moderating role of DTCA knowledge
on perceived attention to risk disclosure (Aiken & West, 1991). Therefore, H7a was supported.
The main and moderating effect hypotheses are summarized in Table 12.
Hypotheses 8, 9, and 10: Mediating Effects of Perceived Attention
Hypotheses 8, 9, and 10 suggested that perceived attention would mediate the effects of
prominence, DTCA knowledge, and their interaction on consumer memory of risk information,
including recall and recognition. In particular, H10 represents a mediated moderation
relationship. A mediated moderation refers to the extent to which an intervening variable
mediates the effect of a more distal independent variable at different levels of the moderator
(Baron & Kenny, 1986).
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Figure 2. Prominence × DTCA Regulatory Knowledge on Perceived Attention

To examine the hypothesized mediations, the researcher adopted the bootstrap approach
outlined by Preacher and Hayes (2004). The bootstrapping method is similar to the Sobel (1982)
test, but is suggested as a superior alternative if raw data are available (Homburg, Wieseke, &
Bornemann, 2009). Further, Zhao, Lynch, and Chen (2010) note that in testing the significance
of an indirect effect between predictors and criterion variables, the bootstrap approach is more
rigorous and powerful than Sobel. The researcher estimated the indirect effects of the predictors
through the mediator variable on the dependent variables and repeated the sampling 5000 times
(Zhao et al., 2010). To secure consistency between the main effect and mediation tests, the same
control variables were entered in the bootstrap macro.
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Table 12. Summary of the Main and Moderating Effect Hypotheses
Hypotheses

Predictors

Outcomes

Results

H1
H2
H3

Prominence
Prominence
Prominence

Perceived Attention
Recall
Recognition

Supported
Not supported
Supported

H4
H5
H6

DTCA Knowledge
DTCA Knowledge
DTCA Knowledge

Perceived Attention
Recall
Recognition

Supported
Not supported
Supported

H7a
H7b
H7c

Prominence × DTCA Knowledge
Prominence × DTCA Knowledge
Prominence × DTCA Knowledge

Perceived Attention
Recall
Recognition

Supported
Not supported
Not supported

According to the suggested steps by Zhao et al. (2010) for mediation analysis, the
mediating role of perceived attention was denoted as (a × b) and the direct effects of independent
variables on dependent variables were denoted as (c) with a 95% confidence interval (CI), along
with 5000 bootstrap samples.
First, to examine the mediating role of perceived attention between prominence and
recall, variables were submitted to the Preacher-Hayes (2008) bootstrap macro in SPSS 21. In the
first analysis, the IV was prominence and the mediating variable (M) was perceived attention.
The DV was recall score. The results showed that perceived attention had indirect-only
mediation effects (a × b = .08) between prominence and recall, with a 95% CI excluding zero
(.0144 to .1704). The direct effect c (.14) was not significant (p > .05). This indirect-only
mediation overlaps with Baron and Kenny’s (1986) full mediation (Zhao et al., 2010). The
results support H8a.
The same procedure was performed on recognition. The results showed that perceived
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attention had complementary mediation effects (a × b = .31) between prominence and
recognition, with a 95% CI excluding zero (.0483 to .6374). The direct effect c (.75) was
significant (p < .05). Specifically, a × b × c (.23) was positive, suggesting a complementary
mediation (Zhao et al., 2010). The complementary mediation indicates that researchers need to
consider the likelihood of an omitted mediator in the direct path, even though the hypothesized
mediator was identified consistent with the researcher’s theoretical framework. The
complementary mediation overlaps with Baron and Kenny’s partial mediation (Zaho et al.,
2010). Further, complementary mediations have been referred to as “consistent” models or
“positive confounding” (Shrout & Bogler, 2002), From the bootstrap perspective, the results of
this study support H8b, while suggesting consideration of a possibly omitted mediator in the
direct path between prominence and recognition.
To test H9a and H9b, the same approach was employed on recall and recognition. The
independent variable was DTCA knowledge, perceived attention was a mediator, and recall and
recognition were dependent variables. The results showed that perceived attention had indirectonly effects (a × b = .04) between DTCA knowledge and recall, with a 95% CI excluding zero
(.0135 to .0786). The direct effect c (-.03) was not significant (p > .05). H9a was supported.
As to recognition, the results showed that perceived attention had indirect-only effects (a
×

b = .19) between DTCA knowledge and recognition, with a 95% CI excluding zero (.0545 to

.2911). The direct effect c (.04) was not significant (p > .05). H9b was supported.
Finally, to test H10a and H10b, the interaction term of prominence and DTCA
knowledge (IV) was entered in the bootstrap macro with perceived attention (M) and recall and
recognition (DVs). The results showed that perceived attention had indirect effects (a × b = -
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.13) between the interaction of prominence and DTCA regulatory knowledge, and recall, with a
95% CI excluding zero (-.2941 to -.0194). The direct effect c (.29) was not significant (p > .05).
These results indicate that the interaction of prominence and DTCA regulatory knowledge had
significant interaction effects through perceived attention on recall. To pinpoint the moderated
mediation pattern, the Johnson-Neyman method was employed. The results showed that when
DTCA regulatory knowledge was one standard deviation (SD) below the mean (.0409 to .2675)
and was the mean (.0165 to .1630), perceived attention mediated the prominence effects on
recall, with a 95% CI excluding zero. However, when DTCA regulatory knowledge was plus one
SD from mean, the mediating effects of perceived attention was not significant, with a 95% CI
including zero (-.0673 to .0989). These results supported H10a (moderated mediation).
The same procedure was performed on recognition. To test H10b, the interaction term of
prominence and DTCA regulatory knowledge (IV) was entered in the bootstrap macro with
perceived attention (M) and recognition (DV). The results showed that perceived attention had
indirect effects (a × b = -.47) between the interaction of prominence and DTCA regulatory
knowledge, and recognition, with a 95% CI excluding zero (-.9906 to -.0759). The direct effect c
(-.48) was not significant (p > .05). These results indicate that the interaction of prominence and
DTCA regulatory knowledge had significant interaction effects through perceived attention on
recognition. To pinpoint the moderated mediation pattern, the Johnson-Neyman method was
employed. The results showed that when DTCA regulatory knowledge was one standard
deviation (SD) below the mean (.1554 to 1.0272) and is the mean (.0554 to .6201), perceived
attention mediated the prominence effects on recognition, with a 95% CI excluding zero.
However, when DTCA regulatory knowledge was plus one SD from mean, the mediating effects
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of perceived attention were not significant, with a 95% CI including zero (-.2712 to .3793).
These results supported H10b (moderated mediation). The mediation test results are summarized
in Table 13.

Table 13. Summary of the Bootstrap Mediation Test Results
Hypotheses
H8a
H8b
H9a
H9b
H10a
H10b

Predictors (IVs)
Prominence
Prominence
DTCA Knowledge
DTCA Knowledge
Prominence × DTCA Knowledge
Prominence × DTCA Knowledge

Mediators (M)
Perceived Attention
Perceived Attention
Perceived Attention
Perceived Attention
Perceived Attention
Perceived Attention

Outcomes (DVs)
Recall
Recognition
Recall
Recognition
Recall
Recognition

Results
Supported
Supported
Supported
Supported
Supported
Supported
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CHAPTER 5: DISCUSSION
Summary of Major Findings
The current research addresses how consumers’ DTCA regulatory knowledge and
varying levels of risk disclosure prominence affect consumers’ risk disclosure coping strategies
directly. Further, this research examines how DTCA regulatory knowledge moderates the risk
disclosure prominence effects on consumers’ perceived attention to and memory of risk
information. DTCA regulatory knowledge was found to affect how consumers process risk
information from DTC ads. The findings illuminate the dynamic mechanisms of consumer risk
disclosure processing, and thereby inform how fair balance can be understood from the
consumer perspective. This research suggests that risk disclosure prominence may work
differently depending on varying levels of consumer knowledge about the role of FDA for
DTCA. This has an important consumer education and public health implications because
consumes’ informed health decisions can be affected by DTCA regulatory knowledge. This
research reveals that simply focusing on risk disclosure provision in DTCA may fail to
illuminate true risk communication effectiveness.
In addition, pharmaceutical marketers could benefit from the findings of the current
research because understanding in which conditions the message prominence effects are
enhanced or reduced provides important insight into the advertising segmenting and design.
From the consumer education perspective, the current research findings imply that consumer
marketplace knowledge should be an important consideration in their health decision making and
therefore the FDA and pharmaceutical marketers may need to exert more efforts to promote
consumers’ marketplace literacy beyond simply providing important health risk information in

86
DTCA. In particular, consumers’ capacity to recognize important health risk information was
significantly improved when DTCA regulatory knowledge was high. When the DTCA regulatory
knowledge level was low, more prominent risk disclosure was more effective.
As has been well-documented, risk disclosure availability is critical in consumers’ health
decision making (e.g., Kavadas et al., 2007; Mazis & Staeliln, 1982; Stewart & Martin, 2004).
However, the DTCA literature has underexplored how varying levels of DTCA regulatory
knowledge affect such decisions. Despite the severe controversy over DTCA for the last decades,
a dearth of research on consumers’ cognitive processing of risk disclosure in DTCA might have
led to an incomplete view of the impact of DTCA on consumers. From the public health
perspective, identifying a way of more effective risk disclosure provision has importance. On the
pharmaceutical marketer’s end, it could be possible through enhancing risk disclosure
prominence. On the consumer’s end, sound health decision making using DTCA can be
improved through enhancing DTCA regulatory knowledge. Taken together, those involved in
DTCA practice and consumer education can benefit from consumer-oriented information
processing principles (Boush et al., 2009; Mazis & Staelin, 1982; Richard, 1990).
In seeking to advance our understanding of consumer information processing mechanism
of risk disclosure, this research also attempts to investigate a mediating cognitive factor (i.e.,
perceived attention) between DTCA regulatory knowledge and memory as well as between
prominence and memory. In doing so, this research shows that both consumer and message
factors can contribute to enhanced consumer involvement in risk disclosure processing. By
testing different levels of DTCA regulatory knowledge and risk disclosure prominence, this
research suggests that those involved in educating consumers about marketplace and designing
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DTCA risk disclosure need to take such consumer and message factors into account.
Overall, the findings of this research supports the theoretical premise that consumer
responses to the ad are affected by varying levels of DTCA regulatory knowledge and risk
disclosure prominence. Specifically, highly knowledgeable consumers were more likely to
memorize important health risks from the DTC ad in general. On the other hand, prominent
disclosure was more effective among less knowledgeable consumers, indicating that message
effects could vary depending on consumers’ individual differences in cognitive variables (e.g.,
Petty & Cacioppo, 1986; Petty & Cacioppo, & Shumann, 1983). Improved recall and recognition
scores clearly show that high levels of consumer literacy about the FDA’s regulatory role for
DTCA play a role in consumers’ health information coping strategies.
Before discussing the implications of the research findings in more detail, the major
findings are summarized as follows: (1) higher DTCA regulatory knowledge enhanced consumer
attention to and recognition of risk information in the DTC ad; (2) DTCA regulatory knowledge
moderated the prominence effects such that among less knowledgeable consumers the
prominence effects were maximized, whereas the effects were minimal among more
knowledgeable consumers; (3) higher prominence were more effective for attention and
memory; (4) DTCA regulatory knowledge and prominence effects operated through perceived
attention on consumer memory of risk information. Taken together, the overall findings support
the current study’s theoretical framework. In the following sections, the theoretical, managerial,
and consumer education/public health implications of this research are discussed.

88
Theoretical Implications
The present research contributes to the theory of DTCA in several ways. In general, more
prominent risk disclosure enhances consumer memory of information and thereby could reduce
errors and biases in consumer decision making (Andrews, 2011). Given this, prominent risk
disclosure provision could counterbalance potential misperception about health risks of the
product use (Kozup, Creyer, & Burton, 2003). For instance, Andrews, Netemeyer, and Burton
(2009) found that prominently presented disclosures contribute to reducing misleading
perceptions about ad nutrition disclosures. Therefore, consumers need to be informed about
important product’s attributes including benefit and risk information, through prominent
information presentation, so that they can make informed health decisions.
However, are the prominence effects always consistent? In the current research, DTCA
regulatory knowledge was found to not only moderate such effects but also directly affect
consumers’ coping strategies of risk disclosure in DTCA. This is an interesting finding in that
prior research has exclusively examined the role of general health literacy regarding consumer
health information processing (e.g., Baer, Allen, & Braun, 2000; Wolf, Davis, Tilson, Bass, &
Parker, 2006; Kickbusch & Ratzan, 2001). DTCA regulatory knowledge has been largely
ignored in the literature despite its potential consequences on consumer response to the ad.
A few DTCA studies have examined the role of consumers’ subjective knowledge about
health and medicine in general (e.g., An, 2007). However, DTCA regulatory knowledge may
represent a distinct aspect of consumers’ cognitive structure regarding prescription marketplace.
While research on health literacy focuses more on particular health issues (Chang, 2008; Jorm,
Barney, Christensen, Highet, Kelly, & Kitchener, 2006), DTCA regulatory knowledge represents
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consumers’ marketplace persuasion knowledge as a DTCA persuasion coping strategy.
In this regard, Friestad and Wright (1994) propose that marketplace beliefs consist of
three broad knowledge dimensions including topic knowledge, agent knowledge, and persuasion
knowledge. Among the three, in the current research, DTCA regulatory knowledge was
conceptualized as consumers’ persuasion knowledge about the FDA’s regulatory role for DTCA.
It is possible that some may conceptualize DTCA regulatory knowledge as agent knowledge,
because it may also represent consumers’ awareness of how pharmaceutical advertisers must
comply with the FDA regulation. However, beyond such classification, a more important point
of DTCA regulatory knowledge may be that such marketplace knowledge enables consumers to
recognize, analyze, interpret, evaluate, and remember persuasion attempts, and to select and
execute coping tactics regarding DTCA health claims, including benefit and risk information
(Boush et al., 2009; Friestad & Wright, 1994). In this sense, borrowing from the term used by
Friestad and Wright (1994), this research views DTCA regulatory knowledge as health
consumers’ DTCA health information coping strategy. Although various types of marketplace
knowledge can be conceptualized and operationalized, this study is one of the first steps to
empirically examine the conceptual framework of PKM in the context of DTCA.
In addition, the moderating role of DTCA regulatory knowledge on the prominence
effects deserves attention. The regression slope analyses clearly support the theoretical prediction
of the current research on the interactive relationship between DTCA regulatory knowledge and
prominence on consumer response to the ad. As DTCA regulatory knowledge increased, the
prominence effects became less significant, whereas as DTCA regulatory knowledge decreased
the prominence effects became more significant. One possible interpretation of this finding is
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that although prominence has an impact on consumer attention to and memory of risk
information in general, the effects would be more significant among less knowledgeable
consumers than more knowledgeable consumers. As discussed, high DTCA regulatory
knowledge consumers are more likely to easily locate and utilize risk information from DTCA,
and therefore they are less likely to be affected by message presentation formats such as
prominence. However, low DTCA regulatory knowledge consumers are less likely to easily
locate and process less prominent risk disclosure, and therefore their attention and memory
performance will largely hinge on the extent of risk disclosure prominence. This implies that
information presented in the way to reduce cognitive efforts (e.g., high prominence) are more
likely to be easily picked out and utilized by low DTCA regulatory knowledge consumers.
However, when risk disclosure was presented less prominently, low DTCA regulatory
knowledge consumers’ information retrieval performance was significantly lower than when risk
disclosure was presented more prominently.
The focus on consumer memory of this research also has a theoretical implication. The
current research addresses important risk disclosure objectives outlined by prior research. Wilkie
(1985) identified nine specific objectives that should be considered in designing risk disclosure:
(1) legibility, (2) prominence, (3) attention value, (4) changing consumer awareness, (5)
changing consumer beliefs, (6) personalizing consumer beliefs, (7) changing consumer attitudes,
(8) changing consumer intentions, and (9) changing consumer behavior. The current research
especially addresses three aspects of consumer response to risk disclosure information:
prominence, attention value, changing consumer awareness. In particular, memory represents
consumer awareness from risk disclosure.
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Additionally, the unique contribution of this research to the DTCA literature is that this
study addresses an under-examined aspect of risk disclosure processing, through investigating a
consumer-side factor: DTCA regulatory knowledge. The above nine risk disclosure objectives
may not be easily achieved without considering consumers’ individual differences in cognitive
structure given the considerable influence of such factors in consumer information processing.
Depending on varying consumers’ cognitive schemas, the risk disclosure effects may vary
considerably. Based on this, understanding the conditions in which the disclosure effects can be
enhanced or reduced, should be considered an important research initiative.
This research also shows that the DTCA literature can benefit from borrowing
information processing theories (e.g., Deshpande & Krishnan, 1981; Mazis & Staelin, 1982).
Despite the potential usefulness of information processing theory in designing consumer
disclosure programs (Jacoby & Small, 1975; Wilkie & Gardner, 1974), little empirical research
has applied and examined the utility of information processing theory with regard to risk
disclosure effects to date in the DTCA context. Recently, some researchers shed new light on the
importance of information processing theory in the context of DTCA research (e.g., Davis &
Meader, 2009, Davis, 2010; Macias & Lewis, 2006; Macias et al., 2007, 2010). The current
research further suggests that more research needs to be conducted using various theoretical
perspectives and various cognitive variables to better understand consumers’ risk disclosure
processing.
In closing this section, simply providing risk disclosure to consumers may be insufficient
because consumers should be able to access and process the information properly. The notion of
DTCA regulatory knowledge suggests that consumer information processing is largely affected
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by the extent to which consumers are knowledgeable about the information category rather than
the content itself. Researchers should examines which cognitive factors can affect risk
information processing. In this sense, while the current research found significant prominence
effects in consistent with previous research findings, more interesting findings may be the direct
and moderating effects of DTCA regulatory knowledge on consumer memory of risk
information.
Finally, one intriguing future research will be on whether higher levels of DTCA
regulatory knowledge could always promote consumers’ sound health decisions. The cognitive
inference literature notes that in some cases consumer expertise may lead consumers to ignore
important information from the environment due to over-confidence (Alba & Hutchinson, 1987).
This implies that high levels of knowledge will not be always beneficial for information
processing. Given that consumers’ knowledge calibration could be distorted by over-confidence,
inaccurate self-knowledge calibration would impede sound health decisions. In this case, even
though important risk information is presented prominently, highly knowledgeable consumers
are likely to disregard it. Researchers describe this phenomenon using a term “a U-tern
relationship” between knowledge levels and consumer information processing accuracy
(Kavadas et al., 2007; Stewart & Martin, 2004). Because addressing this inquiry goes beyond the
current research scope, future research needs to illuminate this theoretical curiosity.

Managerial Implications
The current research provides practical insights into the design and target segmenting of
DTCA. Based on the well-known knowledge that varying levels of risk disclosure prominence
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could lead to disproportional effects on consumer memory of information (Cowley & Barron,
2008), DTC advertisers need to identify optimized levels of prominence when they develop the
design of risk disclosure in DTC ads. For instance, when advertisers present product attribute or
efficacy information, it has been known that more prominent messages are superior to less
prominent ones in term of consumer recall and evaluations (Gupta & Lord, 1998).
However, based on the current research findings, it is hard to say that more prominent
information provision is always the best policy for advertisers. Marketers should consider
relevant consumer characteristics to achieve the intended marketing goals (Cowley & Barron,
2008). Although information prominence increases consumer memory in general, under specific
circumstances prominence may have a minimal impact on consumer evaluations of brands (van
Reijmersdal, 2009).
How can DTC advertisers achieve the intended marketing goals (e.g., market volume
expansion), while simultaneously complying the FDA regulation? The two-sided message
literature suggests useful insights. Two sided message refers to the message that presents both
positive and negative information about the product (Crowley & Hoyer, 1994). Once wellexecuted, two-sided messages can enhance source credibility (Eisend, 2006, 2010), and such
enhanced credibility can increase overall persuasiveness of the messages (Wilson & Sherrell,
1993).
Given reportedly prevalent consumer skepticism in contemporary marketplace (Boush et
al., 2009; Obermiller & Spangenberg, 1998), rightly provided risk disclosure may offset the
negative impression of the product. Specifically, attribution theory suggests that individuals
assign causes to observed behavior to better understand their environment (Eisend, 2010). In this
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regard, acknowledging potential health risks of the drug in ads may positively contribute to
consumer evaluations of the drug and advertiser, because it can be perceived as complying with
the regulation and thereby as credible.
In particular, when consumers’ DTCA regulatory knowledge is high, fair balance
between benefit and risk information would be more beneficial for pharmaceutical advertisers.
This is because most consumers nowadays recognize that DTCA is required to present health
risks of the drug in ads by law. Eisend (2006) notes that consumers’ perceived marketer
compliance to law can positively affect advertising evaluations. Therefore, advertisers need to
comply with the DTCA fair balance requirement not only to avoid legal and ethical accusations,
but also to achieve more favorable consumer reactions. Given that the major marketing goal of
DTCA is to expand prescription volume, fair balanced DTCA can contribute to such marketing
goals, while simultaneously contributing to social responsibility. Currently, this research
phenomenon is not fully examined. More empirical research should provide solid evidence
regarding this theoretical prediction in order to provide practical insights.

Consumer Education and Public Health Implications
The findings of this research also address consumer education and public health
implications. The risk disclosure requirement is based on the assumption that consumers are able
to access and process, and thereby weigh the risks appropriately to make informed health
decisions (Calfee, 2002; Cox et al., 2010). However, an important question remains regarding
how well consumers utilize risk information in the DTC ad. Given that DTCA serves as an
important public health education channel these days, several points need to be noted.
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First, information about the drug's risks as well as benefits should be attended
sufficiently, in order to render them to be stored and retrieved appropriately when consumers
make health decisions. However, concerns about consumers' proper use of health information in
DTCA call for a more meticulous examination about not only the way information is delivered,
but also how consumer factors affect information processing (Mackert, 2011). It is worth noting
generally accepted communication process models such as Mcguire’s (1976) steps in
information processing (i.e., exposure, attention, comprehension, attitude, retention, retrieval,
decision making intentions, and behavior). Recently, Wogalter (2006) refined the McGuire’s
classical information processing model and proposed the communication-human information
processing (C-HIP) model in the context of risk communication. Based on these information
processing models, the point is clear. A message sent by the advertiser is not always interpreted
by the receiver as the sender intended. To better understand this discrepancy, taking consumer
perspectives into account can provide insight into how risk information can be more effectively
communicated (Davis, 2010; Davis & Meader, 2009; Hoek et al., 2011; Mantel, 2010; Menon,
Deshpande, Perri III, & Zinkahn, 2003a, 2003b). Among others, researchers are advised to
examine consumers’ varying cognitive structures to enhance risk communication effectiveness.
Despite the severe debate over the DTCA category, if relevant and timely health risk
information can be conveyed to health consumers, DTCA can contribute to public health as an
important health education source (Kaphingst & Dejong, 2004; Royne & Myers, 2008).
However, the current research shows that the use of risk information from DTCA largely hinges
on consumers’ DTCA regulatory knowledge. When consumers have certain levels of DTCA
regulatory knowledge, the effectiveness of risk disclosure may be ensured. However, when a
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majority of consumers do not have sufficient DTCA regulatory knowledge, the importance of
prominent risk disclosure provision increases. Considering the relatively low consumer DTCA
regulatory knowledge level in the current research sample, the current FDA’s concern about risk
disclosure prominence may be reasonable.
However, in the long term, the current research findings suggest that consumer education
by the FDA and pharmaceutical advertisers may play a promising role for consumers’ informed
health decision making. Hoy and Andrews (2004) note that consumer education by government
agencies, industry trade associations, and consumer advocacy groups can help consumers better
understand complicated ad information. In this regard, the FDA and pharmaceutical
manufacturers’ voluntary association (PhRMA) have exerted efforts to improve consumers’
perception and behavior regarding DTCA. However, the current research suggests that consumer
education about the FDA’s regulatory role for DTCA may also help consumers better cope with
risk disclosure information in DTCA.
In some sense, DTCA regulatory knowledge can be viewed as consumers’ media literacy
as part of overarching marketplace persuasion knowledge. Extending the PKM perspective
(Friestad & Wright, 1994), consumers’ enhanced media literacy about DTCA may improve their
DTCA health information coping strategies. In particular, greater DTCA regulatory knowledge
will improve consumer processing of important health risk information of the prescription
medicine.
As the current research adopts DTCA regulatory knowledge measures from the current
FDA’s webpage, the FDA can provide useful health and media literacy programs on its website
(e.g., For Consumers & Patients). Consumers can benefit from such information sources for not
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only health education but media literacy improvement. In the same manner, consumers can also
obtain a lot of useful educational information from pharmaceutical advertisers’ promotional
websites and various public educational sources. In particular, the Internet serves as an important
health information source (Dutta-Bergman, 2004; Lee, Park, & Widdows, 2009; Suggs, 2006).
Consumer health and media literacy programs should be executed through various media
channels.
Unfortunately, current levels of public understanding of the FDA's regulatory role for
DTCA appeared to be low. Bell, Kravitz, and Wilkes (1999) and Wilkes, Bell, and Kravitz
(2000) examined what assumptions consumers make about the regulation of DTCA. The results
(Wilkes, Bell, & Kravitz, 2000) showed that half of respondents believed that DTCA had to be
submitted to the FDA for prior approval, 43% of them believed that only completely safe drugs
could be promoted directly to consumers, 22% of them believed that promoting of drugs with
serious side effects had been banned, and 21% of them thought that only extremely effective
drugs could be marketed directly to consumers. However, given that all of these statements are
untrue, the results imply that there is a possibility that consumers may have a serious
misunderstanding regarding the DTCA's regulatory context. In particular, as to minorities they
were more misinformed about the DTCA regulation than were white respondents (Bell et al.,
1999). Bell et al. (1999) note that many consumers hold inaccurate beliefs regarding the
regulation of DTCA and this false faith could increase susceptibility to DTCA, because
consumers with erroneous assumptions are more likely to act on them.
The statements employed in previous research on public's knowledge of DTCA
regulation (e.g., Bell et al., 1999; Wilkes et al., 2000) appear to be closely analogous to those
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employed in the current research. This research employed various statements to measure
consumers' DTCA regulatory knowledge, which were borrowed from the FDA's consumer
education webpage. In that regard, the findings of this research provide invaluable consumer
education and public health implications, which is a unique contribution of the current research.
It may be both the FDA's and pharmaceutical marketers' responsibility to inform consumers
about critical aspects of DTCA regulation. To help consumers make better prescription
decisions, both the FDA and pharmaceutical marketers should exert organized efforts to inform
consumers regarding the regulatory context of DTCA through various methods. In the long term,
pharmaceutical marketers should communicate risk information openly and accurately with
consumers. In particular, they need to provide much attention to health risks of the medicine.
From the FDA's perspective, the agency can fully educate the role of promotional
materials or prescription drug brands, the role of drug evaluations, and the need for consumers to
cooperate with health care professionals (Wilkes et al., 2000). Furthermore, health care
professionals can also develop a systematic media literacy program to educate consumers about
the promotional nature of DTCA as well as the regulatory context of DTCA (Bell et al., 1999;
Wilkes et al, 2000) to promote important health care marketplace persuasion knowledge.
Moreover, the public needs to be informed about the limitations of DTCA placed on its
regulation. To do so, Bell et al. (1999) suggest that the development of a media literacy program
that teaches about the nature of pharmaceutical advertisers' persuasive strategies with
cooperation on the part of the FDA, health care professionals, and public health organizations
will contribute to public health. Importantly, health consumers themselves should exert efforts to
make informed and sound health choices based on accurate and comprehensive understanding of
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health information regarding both benefits and risks of medical remedies. For true health
consumerism, it is also individuals' responsibility to behave actively as health consumers.
In this regard, the Pharmaceutical Research and Manufacturers of America’s (PhRMA)
(2009), an organization representing pharmaceutical companies, industry guidelines for DTCA
outline an important premise that:
DTC advertising of prescription medicines can benefit the public health by increasing awareness about
diseases, educating patients about treatment options, motivating patients to contact their physicians and
engage in a dialogue about health concerns, increasing the likelihood that patients will receive appropriate
care for condition that are frequently under-diagnosed and under-treated, and encouraging compliance with
prescription drug treatment regimens.

In the above voluntary guidelines, an important goal of DTCA is well-illustrated. That is,
DTCA should encourage consumers to get proper medical treatment based on proper health
education. Despite potential health risks of the drug, consumers should have a chance to discuss
with their doctors about the advertised drug, in order to find out the best medical remedies to
manage their own health issues. The current research adds that consumers also need to be
educated about the FDA’s regulatory role for DTCA to better cope with DTCA health
information, especially risk disclosure.
In closing this section, there has been a long severe controversy regarding the role of
mass media between its health promotion and worsening functions (Wallack, 1989, 1990).
Proponents believe that mass media can provide the right health information to the right people
in the right way at the right time, whereas critics argue that mass media could be a barrier to
health education because media institutions are supposed to be driven by profit (Wallack, 1989).
However, one thing for sure is that mass media play an important role in communicating relevant
health information to the public, by setting the public’s health agenda and contributing to
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preventive and remedial health behaviors (e.g., McGuire, 1984; O’Keefe & Reid-Nash, 1986).
However, despite the potential contribution of DTCA to public health, the literature has
ignored how risk information can be better communicated from the consumer perspective (Hoy
& Andrews, 2004). Stewart and Martin (2004) note that “regulation of marketing communication
should not be less consumer centric” (p. 190). Although this idea is not original, the complexity
of consumer information processing calls for research that measures consumer response to
disclosure information. Considering the findings of the current research, it is clear that one needs
to consider how consumers actually perceive health risks of the drug and utilize such information
in their health decision making. Among various consumer side-factors, the current research
especially explored the potential role of DTCA regulatory knowledge as pharmaceutical
marketplace persuasion knowledge. Organized efforts to improve consumer DTCA regulatory
knowledge through various education programs could contribute to public health through
consumers’ informed health decision making.
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CHAPTER 6: LIMITATIONS AND FUTURE RESEARCH RECOMMENDATIONS
As with most studies, several important limitations of the study and avenues for future
research warrant mention. First, although the current research employed a professional online
survey company to reach a relatively representative US adult sample, caution should be taken on
generalizing the results to other contexts, because the respondent recruiting method was a
convenience sampling in nature. More often than not, it is not easy for researchers to reach a
fully US representative adult sample due to the limited time and resources. Nevertheless, one
alternative remedy to reduce potential response biases in the data of this study was the utilization
of random assignment (Kerlinger & Lee, 2004; Shadish et al, 2002; Wimmer & Dominick,
2006). The survey software, Qualtrics, allowed the researcher to randomly assign respondents to
each treatment condition. Further, to counterbalance any order effects in multiple choice
questions, the researcher also randomized choice presentation orders for major dependent
variables (e.g., recognition). However, future research needs to examine various contexts and
utilize more representative populations to replicate and extend the current research findings.
Second, when applying the findings of this research to other cultural contexts, careful
considerations should be exerted. Currently, DTCA is allowed in only two countries in the world
(Royne & Myers, 2008): the US and Newzealand. Although many countries currently consider
the legalization of the DTCA practice (e.g., South Korea), most DTCA studies have been
conducted exclusively in the US and Newzealand contexts. In this regard, the interpretation of
the current research findings should be limited to the US context because the regulatory
environment and research participants were based on the US context.
However, a promising future research avenue could address different consumer
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information processing mechanisms across different cultural contexts. For instance, different
styles of risk appraisal or avoidance of uncertainty could influence consumer processing of risk
disclosure in DTCA differently. For instance, it has been well documented that collectivistic and
individualistic cultures have their preferred regulatory orientation. Collectivists are more likely
to be prevention-focused and individualists are more likely to be promotion-focused (Lee, Aaker,
& Gardner, 2000). This implies that consumers’ receptivity of risk disclosure in DTCA or
medical product advertising can be different across different cultural schemas. In a similar vein,
Hoy and Andrews (2004) note that different risk disclosure presentation modalities may work in
different ways across distinct countries. Further, they suggest that risk disclosure research on
cultural differences can contribute to global consumer interests (Hoy & Andrews, 2004). The
current research adds that such program of research can expand the scope of DTCA risk
disclosure research by incorporating global health consumerism perspectives, because health
care empowerment is increasingly receiving global attention.
Third, in terms of the manipulation of risk disclosure prominence, there could be various
considerations and alternatives. According to the FDA’s (2009) draft guidance for risk
communication in DTCA, this research employed several widely used message execution factors
to highlight risk disclosure. However, risk disclosure prominence can be conceptualized and
operationalized in many ways. More often than not, the concept of fair balance is defined in
terms of the relative amount of benefit and risk information (Huh & Cude, 2004; Sheehan, 2007;
Macias et al., 2007). Some studies define prominence in terms of relative placement and
modality of risk information (Davis, 2010). Typographical devices such as box-warnings are also
utilized for operationalizing prominence (Kees, Bone, Kozup, & Ellen, 2008). However, in this
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research, to reflect the FDA’s (2009) current thought on fair balance in DTCA, several message
factors were utilized simultaneously to probe consumers’ net impression other than their
reactions to particular aspects of the ad. Future research can examine risk disclosure prominence
though different conceptualizations and operationalizations.
Fourth, this research did not pay much attention to the interactive roles of benefit and risk
information on consumer response to the ad, because the focus of research was on risk disclosure
prominence. However, an additional analysis revealed that despite the exactly equivalent content
and format for the uses of the drug across different test ads, the perceived prominence of the uses
of the drug (as a confounding check) was slightly different, depending on varying risk disclosure
prominence levels. One intriguing speculation would be that consumer perception could be
affected by the interactive influence of benefit and risk information. In the additional analysis,
the researcher found that as risk disclosure prominence increased, perceived prominence of drug
use information decreased, though it was not statistically significant. One future research avenue
will be examining the interactive effects of benefit and risk information presentation formats on
consumers’ perception. In line with this, the FDA (2009) is concerned about overall impression.
However, what is lacking in the FDA’s guidance for risk communication is the recognition that
surface-level fair balance cannot secure intended risk disclosure outcomes. Consumer perception
will be largely context-driven. A program of research on this research inquiry is warranted.
Fifth, the present research did not address the content effects. However, the content of
risk disclosure itself as well as its format can influence consumer response to the ad. It has been
known that perceived severity of health risks affects consumers’ health behavior (Carpenter,
2010). Varying levels of health risk perception can lead to different response to the ad. Given
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that prescription drugs can be purchased only through prescription from health professionals, it is
implied that prescription drugs’ health risks may be more serious than those of over-the-counter
drugs that can be purchased without prescription. However, different therapeutic categories and
brands may have different health risks and therefore the effects of risk disclosure will be affected
by the health risk content itself. Moreover, it is possible that the format and content of risk
disclosure may interact from one another. Researchers may need to differentiate between the
effects of the content and format of DTCA.
Sixth, this study examined print media type DTC ads even though it was presented in an
online survey through the Internet. A number of branded DTCA websites present information
about the drug including benefit and risk information in a similar manner with print DTCA.
However, various media interfaces have unique technological characteristics. A body of research
has examined branded prescription drug websites to examine the content of DTCA and their
message appeals (e.g., Huh & Cude, 2004; Sheehan, 2007; Wymer, 2010). Such interactive
media may utilize various information provision modalities such as voice and video (Davis,
2010). In line with this, different media interfaces call for different consideration of risk
disclosure presentation (Hoy & Andrews, 2004). For instance, interactivity could be considered
an important factor affecting prominence (Cauberghe & Pelsmacker, 2010). Applying to the
DTCA context, the Internet or mobile devices may lead researchers to conceptualize and
operationalize risk disclosure prominence differently. However, little research has examined the
risk disclosure prominence effects in the rich media contexts. Future research can address how
the different media contexts relate to varying consumer information processing mechanism of
risk disclosure prominence.
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Seventh, although the current research employed a perceived attention measure to assess
consumer attention to risk disclosure in DTCA, a concern could be raised about the self-report
single-item measure for the construct. As discussed in the method section, there is a practical
utility of perceived attention approach. Nevertheless, a more reliable measure will be physiopsychological approaches. In addition, regarding the timing of measuring perceived attention,
there could also be a concern about demand characteristics, because some manipulation checks
of risk disclosure prominence that may signal health risks of the drug were positioned before the
perceived attention measure. Due to a potential discrepancy between objective and subjective
measures, a more objective and accurate measure to assess to what information a person attended
may be via eye-tracking. For instance, when subjects claim to have looked at risk disclosure
information through self-reported answers, it is possible that they did not look at all. This
indicates that subjective self-report attention measures may have limitations and therefore could
serve only as a proxy measure of actual attention. Researchers should pay careful attention to
interpret the results when using subjective measures.
As an alternative for future research, eye tracking approach is a technique whereby
subjects’ eye movements are measured so that the researcher understand where an individual is
looking at any given time, and the sequence in which their eyes are shifting from one location to
another (Poole & Ball, 2005). This method has been used in the advertising literature to
determine what advertisement designs attract the greatest attention (Lohse, 1997) and to
determine if Internet users pay attention to banner advertising on websites (Albert, 2002). Of
course, as with every experimental methods, eye tracking does not represent a perfect approach
for attention research. Rather, there could be a list of cautions that researchers should bear in
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mind when applying the method. Among others, subjects should have well-defined tasks to carry
out so that their eye movements can be appropriately attributed to actual cognitive processing
(Poole & Ball, 2005). That is, eye movements per se cannot guarantee accurate cognitive
processing measurement. Eye tracking researchers can employ various methodological devices
in combination to address this limitation (Poole & Ball, 2005).
Eighth, the measurement of DTCA regulatory knowledge may have limitations. The most
common way to measure knowledge has been multi-item scales¸ having two to four items (e.g.,
Beatty & Smith, 1987; Park et al., 1994). Although good reliabilities have been reported for such
multi-item scales, they were all essentially ad hoc, generated for the first time for the purpose at
hand, and were not validated or employed in another study (Flynn & Goldsmith, 1999). This is
also the case in the current research. Despite the conceptual originality and its public education
and health implications, the multi-item measurement scale of DTCA regulatory knowledge in the
current research shows low reliability (Chronbach’s α = .29). Statistically speaking, when
true/false type test answers are coded as dummy variables to form a composite score to represent
varying knowledge levels, it is likely that the internal consistency value (i.e., Cronbach’s alpha)
for the categorical items is low. For instance, House et al. (2004) measured consumers’ objective
knowledge about the facts and issues concerning genetic modification in food production in
order to examine its effects on consumers’ willingness to accept genetically modified foods, and
found significant knowledge effects. They employed four-item true/false type questions.
However, its measurement scale reliability was relatively low (i.e., Cronbach’s α= .54).
In this case, a more appropriate description for such type of measurement items may be
the percentage of correct answers for each item. In that regard, the current research illustrates the
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descriptive statistics for each item. Nevertheless, it is suggested that future research develops a
reliable measurement scale for DTCA regulatory knowledge so that some degree of
measurement standardization in DTCA research can be attained. At this moment in time,
considering that there is a dearth of research on this construct in the DTCA literature, the
exploratory approach to measuring DTCA regulatory knowledge may be justified.
Ninth, the subjects of the current research consists of higher percentage of males (63.6%)
than that of females (36.4%). This could be a lack of representation of the profile of actual users
of Rx anti-depressant. Future research may employ a more representative sample profile to better
represent the current antidepressant users. However, it is noteworthy that according to CDC, in
terms of gender, during 2007-2010 5.3% of male respondents reported that they have used
antidepressants, while 11.9% have used antidepressants in past 30 days (CDC, National Center
for Health Statistics. Health, United States, 2012). The percentage of male users have rapidly
increased from 1.2% during 1988-1994, to 4.4% during 1999-2002, and to 5.3% during 20072010. Considering the educational role of DTCA, the current research finding may provide
insight into potential antidepressant users’ (i.e., males) response to antidepressant DTCA.
Tenth, the sample of the current research represents general adult consumers rather than
individuals who have been diagnosed with the disease. Approximately 30% of subjects reported
having been diagnosed with mental depression. This could be justified when considering that the
major purpose of DTCA is not only to increase consumer generated prescription volume but also
provoke and facilitate an initial self-diagnosis from DTC ads (Davis, 2006). In the current
research, given its focus on health risk information in DTCA, a list of questions were given to
subjects to probe their direct or indirect experience with adverse reactions after taking a
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prescription drug, including personal experience (48.5%), family (38.3%), relatives (35.2%),
your circle of friends (31.1%), your circle of neighbors (13.6%). These results show that
approximately half of the subjects have experienced any health risks from the use of prescription
drugs and at least 30% of them have indirect experience with health risks regarding prescription
drug use. While individuals with depression diagnosis experience could be an appropriate sample
of antidepressant DTCA research, given the focus of research on risk disclosure processing and
the role of DTCA regulatory knowledge, the use of the current sample seems plausible. Future
research can employ individuals with direct depression experience to examine how DTCA
regulatory knowledge and prominence work differently among such consumers.
Eleventh, future research may need to provide basic information about clinical depression
in the research instrument. According to research, there was significant increase in the proportion
of people recognizing depression in the vignette during 1998-2004 in Australia. For instance,
compared with 1998, in 2004 mental health literacy including depression recognition increased
considerably (Goldney, Fisher, Dal Grande, & Taylor, 2005). In a similar vein, the current
research subjects show a reasonably good understanding of what clinical depression is through
perceived familiarity, subjective knowledge, and perceived importance. Nevertheless, it is
possible that many US consumers may not be able to clearly differentiate between clinical
depression and short periods of sadness. Future research instruments could clarify what clinical
depression is to provide a foundation to research participants.
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Appendix A: Survey Questionnaire
Thank you for your willingness to participate in this study. Ilwoo Ju (Doctoral Candidate) at the
University of Tennessee is the primary investigator of this study, and is attempting to understand the use
of health information among adults.
There are no anticipated risks for study participants. However, if you do not wish to answer a question,
you may skip it. Participation is voluntary. If you wish to quit the project at any time, you can simply
close the survey.
If you have questions about the study or the procedures, you may contact the primary researcher Ilwoo Ju
by mail at 401 Student Services Building, Knoxville, TN 37996, by phone at (865) 318-4004, or by email at iju@utk.edu. If you have questions about your rights as a participant, contact Brenda Lawson in
the Office of Research & Engagement at (865) 974-7697 or blawson@utk.edu.
The information you provide will be anonymous. You will not be identified individually at any stage of
the study. The data and your informed consent will be stored in a secured place (the University of
Tennessee Communication College Doctoral Office) during the analysis for 3 years and will be destroyed
afterwards. You must be age 18 or older to participate.
By clicking this link, you indicate your consent to participate and that you are at least 18 years old.
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The primary focus of this survey is on your thoughts and feelings about health issues in
general. Please read carefully and answer the following questions.
Q1) How would you rate your overall health at the present time?
poor
fair
good
excellent




Q2) How familiar would you say you are with the issue of clinical depression?
not at all
moderately
familiar
familiar






Q3) How knowledgeable would you say you are about clinical depression?
not at all
moderately
knowledgeable
knowledgeable







very familiar


very
knowledgeable


Q4) How important is the issue of clinical depression to you?
not at all
important






moderately
important






very
important


Q5) Have you ever been diagnosed with clinical depression?
Yes _____ No_____
Q6) In the following questions, please report your opinions about prescription drug advertising.
Note: “Prescription drug” refers to a drug you can get only with a doctor’s prescription.
6-1) Prescription drug advertising is truth well told.
strongly
somewhat neither agree nor
disagree
disagree
disagree
disagree





somewhat
agree
agree



strongly
agree


6-2) Prescription drug ads generally present a true product picture.
strongly
somewhat neither agree nor somewhat
disagree
agree
disagree
disagree
disagree
agree







strongly
agree


6-3) We can depend on getting the truth in most prescription drug advertising.
strongly
disagree somewhat neither agree nor somewhat agree

strongly
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disagree




disagree


disagree


6-4) I am accurately informed by most prescription drug ads.
strongly
somewhat neither agree nor
disagree
disagree
disagree
disagree





agree




agree


somewhat
agree
agree



strongly
agree


6-5) Prescription drug advertising is a reliable source of information.
strongly
somewhat neither agree nor somewhat
disagree
agree
disagree
disagree
disagree
agree







strongly
agree


6-6) Prescription drug advertising’s aim is to inform the consumer.
strongly
somewhat neither agree nor somewhat
disagree
agree
disagree
disagree
disagree
agree







strongly
agree


6-7) Most prescription drug advertising provides consumers with essential information.
strongly
somewhat neither agree nor somewhat
disagree
agree
disagree
disagree
disagree
agree







strongly
agree


6-8) Prescription drug advertising is informative.
strongly
somewhat neither agree nor somewhat
disagree
disagree
disagree
disagree
agree






strongly
agree


agree


Q7) For each statement, please check a box to report your beliefs about prescription drug
advertising.
Note: “Prescription drug” refers to a drug you can get only with a doctor’s prescription.
7-1) The FDA bans consumer-directed ads for prescription drugs that have serious health risks.
Yes______ No______ Don’t know ______
7-2) The FDA requires drug companies to use hard-to-understand medical language in
prescription drug ads directed to consumers.
Yes______ No______ Don’t know ______
7-3) The FDA works with drug companies to create prescription drug ads directed to consumers.
Yes______ No______ Don’t know ______
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7-4) The FDA approves prescription drug ads before they are seen by the public.
Yes______ No______ Don’t know ______
7-5) The FDA regulates the design of prescription drug ads directed to consumers.
Yes______ No______ Don’t know ______
7-6) The FDA conducts research to examine consumer attitudes and behaviors toward
prescription drug advertising.
Yes______ No______ Don’t know ______
Q8) Please report your past experiences with prescription drugs.
Q8-1) Have you ever experienced adverse reactions after taking a prescription drug?
Yes______ No______ Don’t know ______
Q8-2) Has anyone in your family experienced prescription drug adverse reactions?
Yes______ No______ Don’t know ______
Q8-3) Has anyone among your relatives experienced prescription drug adverse reactions?
Yes______ No______ Don’t know ______
Q8-4) Has anyone within your circle of friends experienced prescription drug adverse reactions?
Yes______ No______ Don’t know ______
Q8-5) Has anyone within your circle of neighbors experienced prescription drug adverse
reactions?
Yes______ No______ Don’t know ______
Q9) Please check a box to indicate your agreement with the following statement.
“If someone hasn’t experienced prescription drug adverse reactions by now, he or she is not
likely to experience them later in life.”
strongly
disagree

disagree

somewhat
disagree

neither agree
nor disagree

somewhat
agree

agree

strongly
agree















Q10) In the past six months, how often have you seen, read, or heard instances where the health
risks of prescription drugs are depicted or discussed in the following media types?

151
occasion
ally

never
Television news,
documentaries, and current
affairs.

very
often















Television entertainment
programs (e.g., soap operas,
sitcoms, drama, movies).















Articles in newspapers and
magazines.















Non-advertising information
from the Internet.















Imagine that you feel like you may be
clinically depressed and have just come
across the webpage for a new
prescription medicine for depression.
Please read the ad as you would if you
were at risk of depression in your real
life.

152
The following questions are about the ad you just saw. Please read and answer them
carefully.
Q11) The ad presented information about the uses and health risks of Luminexell. Please check a
box that best represents your thoughts.
The ad presented the uses of Luminexell more prominently than its health risks

The ad presented the health risks of Luminexell more prominently than its uses

The ad presented the uses and health risks of Luminexell equally in terms of prominence 

Q12) How prominently do you think the ad presented the uses of Luminexell?
not at all
prominently

1


extremely
prominently

2


3


4


5


6


7


Q13) How prominently do you think the ad presented the health risks of Luminexell?
not at all
prominently

1


extremely
prominently

2


3


4


5


6


7


Q14) In the following, for each statement please check a box to indicate your level of agreement.
neither
strongly
somewhat agree somewhat
strongly
disagree
agree
disagree
disagree
nor
agree
agree
disagree
It was easy to find the
information about the health
risks of Luminexell

1


2


3


4


5


6


7


It was easy to focus on the
information about the health
risks of Luminexell

1


2


3


4


5


6


7
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I liked the way the ad
presented the information
about the health risks of
Luminexell

1


2


3


4


5


6


7


Q15) How much attention did you pay to the information about the health risks of Luminexell?
moderate
great
no attention
attention
attention














Q16) The ad presented the health risks of Luminexell. In the box below, please write all the
health risks of Luminexell you can recall from the ad.

Q17) How easy do you feel it was to recall the health risks of Luminexell presented in the ad?
extremely
easy












extremely
difficult


Q18) Which of the following were presented in the ad as the health risks of Luminexell? Please
check all that apply.











Seizures
Decrease in white blood cells
High fever
Lightheadedness upon standing
Trouble swallowing
Rigid muscles
Impairment in motor skills
Insomnia
Increased heart rate
Abnormal facial movements

Q19) Given the above check list, how easy do you feel it was to recognize the health risks of
Luminexell presented in the ad?
extremely

extremely
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easy
difficult







Q20) Imagine that you take Luminexell to treat clinical depression. Then I would like you to
think of people your own age and sex who also take the drug. Compared with other people
your age and sex, how would you rate your chances of experiencing the adverse reactions of
Luminexell?
far less
likely

less
likely





slightly
less likely

about the
same
likelihood

slightly
more likely

more
likely

far more
likely











Q21) What do you believe is the chance that you will experience the adverse reactions of
Luminexell?
no
chance
0


50-50
chance
1


2


3


4


5


6


7


8


certain
to
happen
10


9


Q22) What do you believe is the chance that the average person your age and sex will
experience the adverse reactions of Luminexell?
no
chance
0


50-50
chance
1


2


3


4


5


6


7


8


9


certain
to
happen
10


Q23) How much personal control do you feel you have over the chances of experiencing the
adverse reactions of Luminexell?
no
control
0


1


2


3


4


moderate
control
5


6


7


8


9


complete
control
10


Q24) If you experience the adverse reactions of Luminexell, how serious do you believe they
would be?
not at all
moderately
extremely
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serious
1


2


serious
4


3


5


Q25) How safe would you say Luminexell is?
not at all
safe
1
2
3
4





6


5


6


serious
7


extremely
safe
7


Q26) If you were to use a prescription drug for treating depression, how likely would you be to
choose Luminexell?
not at all
likely
1


2


3


4


5


6


extremely
likely
7


Q27) Imagine that you take Luminexell to treat depression. For each statement, please check a
box to indicate your agreement.

strongly
somewhat
disagree
disagree
disagree
I would like to learn more about the
health risks of Luminexell
When I come across other useful
information about the health risks
of Luminexell, I would like to
retain it
I would like to use various media
sources to get more information
about the health risks of Luminexell

neither
agree somewhat
strongly
agree
agree
agree
nor
disagree











































Q28) Please check your gender. Female_____ Male_____
Q29) How old are you? ______ years old
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Q30) What is your ethnic background?
White, not Hispanic _____ Hispanic, of any race _____ Black, not Hispanic _____
Asian or Pacific Islander ________ American Indian, Eskimo, or Aleut _______
Other (Please specify) _____

Q31) What is the highest level of education you received?
1.
2.
3.
4.
5.
6.
7.
8.
9.

Did not finish high school
Completed high school but no college education
Some college education but no degree
Associate’s degree (examples: AA, AS)
Bachelor’s degree (examples: BA, BS)
Attended graduate school but no degree
Master’s degree (examples: MA, MBA)
Professional degree (examples: JD, MD)
Doctorate degree (examples: PhD, EdD)

Q32) What is your annual household income?
1.
2.
3.
4.
5.
6.

lower than $25,000
$25,000 ~ $49,999
$50,000 ~ $74,999
$75,000 ~ $99,999
$100,000 ~ $149,999
$150,000 or higher

1.
2.
3.
4.
5.

Smartphone
Tablet PC
Laptop computer
Desktop computer
Other __________________(please specify)

Q33) What type of device did you use to participate in this survey?
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Appendix B: Low Prominence Ad Stimulus
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Appendix C: High Prominence Ad Stimulus
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Appendix D: Exploratory Ad Stimulus
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